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 Steroid sulfatase (STS) is considered to be one of the key enzymes contributing to 
the development of breast cancer.  It catalyzes the hydrolysis of inactive sulfated steroids such as 
estrone sulfate (ES) to inorganic sulfate active steroids such as estrone (E1), a precursor to 
estradiol (E2), a key stimulator for breast cancer development.  Inhibitors of STS are currently 
being pursued in both academia and industry as potential drugs for treating breast cancer.   
 A series of 4-substituted estrone and estradiol derivatives were examined as inhibitors of 
STS. Inhibition of STS with 4-FE1, an irreversible inhibitor of STS previously studied in the 
Taylor group, can be enhanced by introducing a hydrophobic benzyl group at the 17-positon of 
4-FE1.  As with 4-FE1, the inhibition was concentration and time-dependent.  Only 14% of the 
activity could be recovered after extensive dialysis.  Introducing substituents at the 2-position of 
4-formyl estrogen derivatives resulted in loss of concentration and time-dependent inhibition and 
a considerable decrease in inhibitor affinity.  Studies with estrogen derivatives substituted at the 
4-position with groups other than a formyl revealed that a relatively good reversible inhibitor can 
be obtained simply by introducing an electron withdrawing group at this position.  These types of 
inhibitors are non-competitive inhibitors suggesting an alternative steroid binding site.  
 A series of estrone derivatives were examined as photoaffinity labels of STS.  4-
azidoestrone suflate and 4-azidoestrone phosphate exhibited properties that are suitable for 
photoaffinity labeling studies with STS.  These labels may be useful for ascertaining pathways of 
substrate entry into the STS active site.  16-diazoestrone phosphate was not a photoaffinity label 
of STS.  2- and 4-azido estrone and 16-diazoestrone all acted as photoaffinity labels of STS.  
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1.1.1 Estrogen Dependent Breast cancer 
 Despite recent advances in medical breakthroughs, breast cancer still remains one of the 
most prevalent forms of cancer in women, claiming over forty thousand lives a year in the 
United States alone (Briest and Stearn, 2009).  Approximately 30-50% of breast cancers depend 
on the bioavailability of active estrogens, in particular estradiol (E2) for development.  In normal 
cells, E2 is a key regulator in processes involving bone formation, fat metabolism, heart health, 
menstrual cycle, and breast growth.  However, E2 when not under physiological check, can over 
stimulate enzymes and proteins involved in nucleic acid synthesis, as well as activating 
oncogenes leading to cancer development (Clemons and Goss, 2001).    
 It has been well established that blocking E2 from interacting with its receptor results in 
the inhibition of cancer cell growth (Pasqualini et al., 1992).  For decades, this finding has been 
exploited by the drugs such as tamoxifen, an antagonist of the estrogen receptor (ER), to treat 
estrogen dependent breast cancers.  While tamoxifen and its derivatives remains the gold 
standard for the endocrine treatment of breast cancers, their efficacy and safety varies greatly 
between individuals (Briest and Stearn, 2009).  Consequently, alternative treatment options have 
been explored in the past decade.  This led to an increase interest in the key enzymes responsible 






1.1.2 Estrogen Biosynthesis  
 The inhibition of estrogen biosynthesis to block the cancerization effect of estrogen 
provides a rational alternative to tamoxifen.  E2 binds the estrogen receptor, forming a complex 
which enters the nucleus and regulates gene transcription.  Consequently, enzymes synthesizing 
E2 precursors are prime candidates for inhibition.  These enzymes include aromatase, 17-β 
hydroxysteroid dehydrogenases, estrone sulfotransferase, and steroid sulfatase (Figure 1.1) 
















































Figure 1.1  Biosynthesis of estradiol from dehydroepiandrosterone (Clemons and Goss, 2001; 




 Aromatase is responsible for the aromatization of the androgens androestenedione (AE) 
and testosterone (T) into E1 and E2 respectively, a key step in estrogen biosynthesis (Clemons 
and Goss, 2001).  Without aromatase, virtually no estrogen can be biosynthesized.  In post 
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menopausal women, aromatase becomes the primary source for serum estrogen.  It has been 
reported that the levels of aromatase mRNA levels in tumour tissues increase with progressing 
clinical stages of breast cancer (Suzuki et al., 2009).  While this does not necessarily translate 
directly into increased aromatase activity, it does provide evidence for the importance of 
aromatase in the development of breast cancers.  It is not surprising that this enzyme has 
unprecedented popularity as a therapeutic target. 
 Aromatase inhibitors (AIs) such as anastrozole and letrozole are effective inhibitors for 
estrogen dependent breast cancers.  In fact, some studies report higher efficacy with AI treatment 
than with tamoxifen (Gnant et al., 2009).  Unfortunately, despite the effectiveness of AI 
treatment, some women still experience cancer progression and reoccurrence when under 
treatment with AI and tamoxifen (Foster et al., 2008). So while aromatase is a very good target 
for breast cancer, it is clear that other therapeutic targets also need to be explored.  
1.1.4 17β-Hydroxysteroid Dehydrogenase 
17β-Hydroxysteroid dehydrogenases (17β-HSDs) catalyze the reduction of the 17-
ketone moiety on several steroids to their corresponding alcohol derivative utilizing NADH or 
NADPH as cofactors.  17β-HSDs is known to exists as several isoforms, but only 17β-HSD1 and 
17β-HSD2 are known to catalyze the final step of estrogen synthesis, the interconversion of E1 
and E2.   Both isoforms favour the forward conversion from E1 to E2 by 240 fold more than the 
backward conversion from E2 to E1.   Since 17β-HSDs are key regulators of E2 concentrations 
in gonadal and peripheral tissues, they are an attractive target for breast cancer therapeutics.  
However, the similarities between the various isoforms of 17β-HSDs present an obvious problem 





1.1.5 Estrone sulfotransferase 
Estrone sulfotransferase (EST) is responsible for sulfating E1 into estrone sulfate (ES).  
It is widely accepted that sulfated steroids are biologically inactive, and serve mainly as a 
reservoir for their activated counterparts. ES is accepted as the most important source of E1, and 
consequently E2. Stimulating the activity of EST would hence decrease the serum concentrations 
of E1 and E2, both of which are crucial for cancer development (Clemons and Goss, 2001; 
Suzuki et al., 2003). There has been considerable evidence showing that levels of EST mRNA 
and ES are elevated in progressing clinical stages of cancer, suggesting that EST plays a key role 
in regulating the progression of breast cancers (Suzuki et al., 2003; Suzuki et al., 2009). 
However, EST lacks popularity amongst other enzyme targets, partly due to the fact that 
designing drugs to stimulate the activity of EST would be incredibly difficult.  
1.1.6 Steroid Sulfatase 
Steroid sulfatase (STS), one of fifteen known human sulfatases, catalyzes the 
desulfation reaction of sulfated steroids, such as DHEAS into DHEA, and more importantly ES 
into E1 (Hanon et al., 2004). ES has several fold better solubility and half life than its non-
sulfated counterpart.  This allows ES to act as steroid storage pool, with concentrations of ES 
reaching up to ten times E1 in tissues (Hankinson et al., 1995; Utsumi et al., 2000). Due partly to 
this rich substrate pool, STS can produce up to ten times more E1 than aromatase in both normal 
and cancerous tissues (Foster et al., 2008).  In fact, studies suggests that the estrogen formed in 
breast tumours is the result of STS activity and not aromatase (Santner et al., 1984; Masamura et 
al.,1996). Much like other key estrogen biosynthesis enzymes, STS mRNA also increases with 
progressing clinical stages of cancers.  For the most part, higher STS mRNA expression results 
in poorer prognosis and recovery, suggesting STS’ pivotal role in breast tumours (Suzuki et al., 
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2009). These convincing lines of evidence suggest that STS could be an excellent therapeutic 
breast cancer target.  
1.2 Steroid sulfatase 
1.2.1 STS Expression and Location 
 Human steroid sulfatase (E.C.3.1.6.2) is found ubiquitously in virtually all mammalian 
tissues, but localized primarily in skin, fallopian tubes, testis, ovary, adrenal glands, brain, fetal 
lung, endometrium, aorta, kidney, bone, placenta, and breasts (Miki et al., 2002; Foster et al., 
2008).  STS is expressed as a 63-73kDA monomeric protein consisting of 583 amino acid 
residues.   The variation in molecular weight is due to the variation in glycosylation states at four 
possible N-glycosylation sites on the enzyme (Stein et al., 1989).  Mutation studies at two of the 
glycosylation sites, Asn47 (N47Q) and Asn259 (N259Q), resulted in a significantly decline in 
STS activity (Stengel et al., 2008), suggesting the glycosylation states have a critical impact on 
the overall tertiary structure of STS.   
Unlike the other two aryl sulfatases, STS is an integral membrane protein found in the 
rough endoplasmic reticulum, but can also be found in trace amounts in the Golgi, cell surfaces, 
multivesicular endosomes and lysosomes (Stein et al., 1989).  Its property as a membrane bound 
enzyme made it initially difficult to obtain a crystal structure, as well as to work with.  
Fortunately, in 2003 Ghosh et al. were able to resolve the crystal structure of STS at a 2.60 Å 







1.2.2 Crystal Structure of STS 
 
Figure 1.2. STS crystal structure revealing the tertiary mushroom-shape structure (Hernadez-
Guzman et al., 2003) 
 
STS assumes an overall tertiary shape resembling the shape of a mushroom, consisting 
of a polar globular domain and a hydrophobic stem domain.  It is suggested that the enzyme 
anchors into the endoplasmic reticulum (ERit) membrane via the stem or transmembrane 
domain, consisting of two antiparallel hydrophobic α-helices (helices 8 and 9). In addition to 
these two helices, there are two other hydrophobic regions on the globular polar domain that is 
thought to also interact or bind to the ERit membrane (Hernandez-Guzman et al., 2003). The 
polar domain contains several disulfide bonds that would be reduced in the cytoplasmic 
environment; so it has been suggested that it faces the lumen of the ERit.  The four possible 
glysosylation sites on STS are also present on the polar domain (Hernadez-Guzman et al., 2003).   
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The active site lies in a cavity situated at the base of the polar domain, just at the top of 
the two hydrophobic α-helices.  Not surprisingly, the structure of the polar functional domain is 
similar to the other two soluble human aryl sulfatases, arylsulfatase A (ARSA) and arylsulfatase 
B(ARSB).  The location of the active site, which is inside a cavity within STS, has raised several 
speculations on how the substrate may enter or leave the active site (Hernadez-Guzman et al., 
2003).  
1.2.3 Substrate Movement 
 
The two antiparallel hydrophobic α-helices, consisting of 25-30 amino acid residues, 
forms a tunnel 40 Å long that could potentially allow the sulfated substrate to pass from the 
cytosol directly into the active site (Figure 1.3).  The tunnel is comprised mainly of aromatic and 
hydrophobic residues, which could aid the movement of the hydrophobic steroid backbone into 
the active site.  Alternatively, the tunnel could also serve as an exit for the product (Hernadez-
Guzman et al., 2003).   
 
Figure 1.3.  Structure depicting the electrostatic potential of STS and its association with the 
RER.  The black arrows indicate regions of STS-membrane interactions.  The red arrow shows a 
potential tunnel pathway that could allows substrate to enter or product to leave the active site 





Figure 1.4.  Structure of STS showing the three flexible loops in red which may allow substrates 
to enter and leave the active site (Hernadez-Guzman et al., 2003) 
 
An alternative mode of entry to the active site is for the substrate to enter from the 
lumen side via three flexible loops surrounding the active site (Figure 1.4).  In order for this to 
occur, the sulfated substrate first be transported through the ERit membrane via a specific 
transporter into the lumen of the ERit.  The three flexible loops are situated at the top of the two 
α-helices.  The first loop, also known as the “front swing door” is formed by residues Thr470 to 
Thr495 and is located directly in front of the active site.  The second loop, called the “right swing 
door”, is formed from Glu348 to Gly358, and is located just to the right of the first loop.  The 
second loop is proposed to have possible interactions with the ERit.  The third loop or the “left 
swing door” is located to the left of the first loop, and consists of res94-100.  Amongst the 
residues constituting to the third loop, of particular importance is Arg98 and Thr99 which may 
have possible interaction with the 17-hydroxyl or ketone group on the steroid (Hernadez-
Guzman et al., 2003).  The second loop, from Glu348 to Gly358, forms the right swing door, and 
may have association with the endoplasmic reticulum surface.  The third loop is found between 
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residues Ala94 and Gly100, which includes Arg98 and Thr99, forms the left swing door to the 
active site.  Arg98 and Thr99 have been thought to interact with the 17-hydroxyl or ketone group 
of the steroid.  The same mode of entry of the substrate could also serve as the mode of exit for 
the hydrolyzed product.  In this case, the hydrolyzed hydrophobic product could be released into 
the lumen or into the membrane of the ERit through one of the swings doors (Hernadez-Guzman 
et al., 2003).    
 While the most energetically favourable route for substrate entry would likely be via 
the tunnel, and product release exit via one of the flexible loops, there is no evidence to suggest 
this is the case.  These uncertainties shrouding the transport mechanisms within STS could 
present difficulties when designing inhibitors for the enzyme.   
1.2.4 Post-Translational Modification of Aryl Sulfatases 
All aryl sulfatases, including STS, become active only after undergoing an essential 
post-translational modification (Figure 1.5).  In eukaryotes, a conserved cysteine residue is 
converted into a formylglycine by the formyl glycine modifying enzyme.  A similar reaction 
occurs within prokaryotes with the exception that either a conserved serine or cysteine is 
converted (Schmidt et al, 1995).  The formyl group resulting from this reaction becomes 
hydrated and forms an α-formyl glycine (FGly) hydrate, the active catalytic residue of STS.  The 
inability to undergo this post translational modification results in multiple sulfatase deficiency 
(MSD), a lysosmal storage disorder, which is characterized by a significant decrease in activity 
of all sulfatases (Schmidt et al., 1995). 
 
 
Figure 1.5.  The post-translational modification found in all aryl sulfatases (
1995). 
 
1.2.5 Proposed mechanism for Aryl Sulfatases
The functional domain of STS
Nine out of the ten residues that are believed to be important for catalysis in ARSA are found in 
the active site of STS and ARSB (
suggested that the catalytic mechanism for STS, and likely all other ARS, are similar to that 
proposed for ARSA. 
Von Figura and coworkers proposed a general mechanism ARS’s based on the crystal 
structure of ARSA and kinetic studies invol
important steps are highlighted in 
activation of one of the oxygens on the formylglycine hydrate by an aspartate residue acting as a 
general base.   The oxygen performs a nucleophilic attack on the sulphur atom of the substrate, 
which consequently releases the desulfated product as well as forming a sulfated hydrate 
intermediate.  A histidine residue acting as a general acid aids the displacement of the desulfated
product.  The sulfated hydrate then undergoes a general
release inorganic sulfate and forming formylglycine, which is then rehydrate
initial formylglycine hydrate.  A Mg
positively charged lysine aid in stabilization of the substrate during catalysis (
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 shows considerable similarity to ARSA and ARSB.  
Bond et al., 1997; Lukatela et al., 1998). Hence, it has been 
ving ARSA and other common ARS’s.  The 
Scheme 1.  The first step of the mechanism involves the 
-base catalyzed elimination reaction to 
d 
++ in ARSA, or a Ca++ in ARSB and STS, in addition to a 
Boltes et al., 2001)
 
Schmidt et al., 
 







































































Scheme 1.  Proposed general mechanism for arylsulfatases based on ARSA (Boltes et al., 2001) 
 
Figure 1.6.  The active site of steroid sulfatase showing a sulfated formylglycine hydrate 
residue.  The sulphur atom is shown in yellow (Hernadez-Guzman et al., 2003). 
The first step in the mechanism proposed for ARSA depicts the hydrate as being 
unsulfated consistent with the crystal structure of ASA showing the formyl glycine hydrate to be 
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unsulfated (Boltes et al., 2001). However, ARSB and STS crystallize with the hydrate sulfated 
(for example see Figure 1.6).  It is thought that the sulfated hydrate is the resting state of the 
enzyme, or the first step of the mechanism for STS and ARSB.  If this is indeed the case, then 
the initial proposed mechanism for ARSA need to be revised for ARSB and STS.  It could 
simply be that the binding of the substrate to these enzymes somehow induces a conformational 
change that results in the desulfation of the hydrate and initiates the first step of the reaction 
cycle.  Another possibility is that STS and ARSB might simply just crystallize better with the 
hydrate sulfated in the crystallization conditions, which does have sulfate present (Hernadez-
Guzman et al., 2003).     
1.2.6 STS is specific for sulfate esters   
According to recent crystallographic studies, arylsulfatases show structural similarity to 
alkaline phosphatases, which catalyze the hydrolysis of phosphate esters.  The possible 
evolutionary linkage between these two distinct families of enzymes might suggest that they 
could also partially hydrolyze each other’s substrate.  After all, phosphate-esters and sulfate 
esters differ only by one atom and, depending on pH, a single negative charge.  A purified 
alkaline phosphatase from E. coli was found to catalyze the hydrolysis of p-nitrophenyl sulfate 
(PNPS) (O’Brien and Herschlag, 1998).  While the catalytic efficiency was much lower as 
expected than compared to its phosphate substrate, the rate was nonetheless higher than 
compared to non-enzymatic hydrolysis by a water molecule (O’Brien and Herschlag, 1998).  The 
presence of sulfatase activity in alkaline phosphatase prompted the question of whether 
arylsulfatases, such as STS, could also have phosphatase activity.  A substrate analogue of ES, 
estrone phosphate (EP) was the rational candidate to test this question.  Indeed, STS could not 
differentiate between the two compounds in terms of binding.  In fact, the binding of monoanion 
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of EP (Ki=0.17µM, pH 6.0) was significantly better than the natural substrate ES (Ki =1.5µM pH 
6.0), but no explanation is available to as why this is this case.  However, the inhibitory potential 
of EP decreased with increasing pH, at pH 7.0 the Ki of EP is at 0.4 µM compared to that of ES 
at 0.9 µM (Li et al., 1995; Anderson et al., 1995).  The dianion of EP did not bind as well as ES; 
this could be simply because the natural substrate is a monoanion.  However, STS could 
differentiate between ES and EP in terms of catalysis, and only specifically hydrolyzed the 
sulfated ester (Anderson et al., 1995).  The reasons to as why STS can only hydrolyze sulfate 
esters and not also phosphate esters are still unclear.  
1.3 STS Inhibitors 
1.3.1 Reversible inhibitors 
There have been few reversible inhibitors of STS reported.  The first were vanadate and 
sulfite which showed decent micromolar potency (Dibbelt and Kuss, 1991) (Figure 1.7).  Sulfate 
itself however is not a good inhibitor, suggesting that the hydrolysis of the sulfate ester bond 














1.1 1.2 1.3  
Figure 1.7.  Vanadate, sulfite, and sulfate as initial inhibitors of STS 
Not surprisingly, the first designs of reversible inhibitors of STS were substrate analogs 
of ES by replacement of the 3-O-sulfate ester.  Many of them, as listed in Table 1.1, were not 
very effective inhibitors, with the exception of the phosphate replacement such as that found in 
EP, which showed promising inhibition with Ki in the submicromolar range at pH’s less than 7 
(Li et al., 1995).  Other potent substrate analog inhibitors include 17α-phenyl and benzyl 
substituted estradiol derivatives exhibiting Ki in the low nanomolar range as shown in Table 1.2 
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(Poirier and Boivin, 1998; Boivin et al., 2000). Increase in potency was also observed with the 
introduction of alkyl chains at the 17-position of estradiol up to octyl length (Boivin et al., 2000).  
It is likely that the increased inhibition of these compounds is due to their hydrophobic 
interaction with the hydrophobic transmembrane helices.   
Table 1.1.  Estrone-3-sulfate mimics as reversible inhibitors of STS   
O
R  
Compound R group Inhibition Reference 
1.4 SO2Cl 92% at 300µM Li et al., 1993 
1.5 SO3
-K+ 40% at 300µM Li et al., 1993 
1.6 SO2NH2 45% at 300µM Li et al., 1993 
1.7 SO2F 44% at 300µM Li et al., 1993 
1.8 SO2CH3 36% at 300µM Li et al., 1993 
1.9 NHSO2CH3 IC50 = 10.20 µM Selcer et al., 1996 
1.10 NHCOCF3 IC50 = 8.7 µM Selcer et al., 1996 
1.11 CH2SO3
- Ki = 140 µM Li et al., 1995 
1.12 OP3
2- Ki = 0.4 µM Li et al., 1995 
 
Table 1.2. 17-substituted analogs as reversible inhibitors of STS (Poirier and Boivin, 1998; 





Compound R group IC50 (nM) 
1.13 (CH2)2CH3 5640 
1.14 (CH2)3CH3 3490 
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1.15 (CH2)4CH3 1980 
1.16 (CH2)5CH3 930 
1.17 (CH2)6CH3 780 
1.18 (CH2)7CH3 440 
1.19 (CH2)7CH3 1000 
1.20 CH2Ph-3’-Br 24 
1.21 CH2Ph-4’-t-Bu 28 
 
 In addition to substrate analogue inhibitors, there are 3 classes of very potent non-
steroidal STS inhibitors worth mentioning: madurahydroxylacetone thiosemicarbazones, aryl 
piperizines and arylsulfonylureas.  The general structures for these compounds are shown in 
Figure 1.8.  Compound 1.22, a madurahydroxylacetone thiosemicarbazones derivative, has an 
IC50 of 460nM and Ki of 350nM with purified STS (Jutten et al., 2002).  Two potent piperizine 
derivatives include compound 1.23 and 1.24, which have IC50s of 47 and 78 nM respectively 
(Hejaz et al., 2004).  An arylsulfonylurea derivative, compound 1.25, was shown to be a 
































1.22   R = c-hexyl 1.23   R = CN




Figure 1.8.  General structures for madurahydroxylacetone thiosemicarbazones, aryl piperizines 
and arylsulfonylureas. 
1.3.2 Irreversible inhibitors 
The majority of inhibitors developed for STS are irreversible inhibitors and the 
majority of these irreversible inhibitors are aryl sulfamates (ArO-SO2NH2).  The literature on this 
class of inhibitors is vast and so only key examples will be discussed.  Two original inhibitors of 
this class of this class are EMATE and 667 COUMATE (STX64), shown in Figure 1.9 
(Bojarova and Williams, 2009). EMATE was one of the first potent inhibitor for STS with IC50 
value of 100 nM and Ki of 670 nM with STS in placental microsomes (Purohit et al., 1995). 
There have been several mechanisms suggested for the inhibition of STS by aryl sulfamates 
(Schemes 1.2 A-D). The first mechanism A suggests that the sulfamate inhibitor first forms a 
Schiff base with the active site residue.  The intermediate complex is then hydrolyzed to release 
the phenolic product while the sulfamate moiety remains and inhibits the enzyme (Woo et al., 
2000). However, non hydrolysable N-sulfamate and S-sulfamates did not exhibit irreversible 
inhibition, suggesting that the hydrolysis of the ArO-S bond is essential for inhibition to occur 
(Bojarova et al, 2008). Bojarova et al. suggested a second mechanism B beginning with a SN2 
attack by the hydrated FGly on the sulfur atom, which consequently displaces the steroid portion 
of the inhibitor.  The reformation of the FGly generates a free sulfamate, which then can react by 
the mechanism proposed in A.  However, incubation of STS with sulfamic acid did not result in 
inhibition.  A third mechanism C involves an active site base catalyzed reaction, releasing the 
product and forming HNSO2.  HNSO2 is a highly reactive electrophile which can react both 
specifically and non-specifically with proximal nucleophiles. This mechanism is highly 
supported as multiple labeling of STS by aryl sulfamates is observed. (Bojarova et al, 2008). A 
fourth possible mechanism D involves a nucleophilic attack on the sulfur atom of the inhibitor by 
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a nucleophile other than the FGly hydrate.  This reaction forms a covalent adduct with the active 
site nucleophile and displaces the phenolic product.  However, N,N-dialkyl sulfamates which 
react solely by SN2 mechanism are not inhibitors of STS early reference .  One explanation to 
account for this observation is the sterics of N,N-dialkyl sulfamates could prevent the SN2 attack 












Figure 1.9.  Structures of two potent STS inhibitors: EMATE and 667 COUMATE (Bojarova 
















































































However, the hydrolysis of EMATE by STS yields E1, which is highly undesirable for 
a cancer inhibitor.  In fact, oral administration of EMATE in rats results in higher observed 
estrogenic activity than oral administration of E1 (Elger et al., 1995).  Studies later report that 
this enhanced activity is due to the sulfamates ability to bind to red blood cells (RBCs), 
consequently allowing them to bypass first pass metabolism in the liver (Elger et al., 2001). To 
overcome this problem, the estrogenic backbone was replaced with a coumarin core.  The result 
was STX64, also known as 667 COUMATE, a potent non-estrogenic inhibitor of STS (Ahmed et 
al., 2001).  In 2005 STX64 passed Phase I clinical trials, but unfortunately no further clinical 
studies have been reported with this or any other sulfamate based STS inhibitors (Stanway et al., 
2007).  
Two reasons for the sulfamate’s incomplete success are partly due to their instability and 
non-selectivity.  Sulfamate based inhibitors decompose in solution into their corresponding 
phenols (Nussbaumer and Billich, 2004).  In addition, they are also very potent competitive 
inhibitors of carbonic anhydrase (CA), commonly found in RBCs, with IC50 at 25nM (Ho et al., 
2003).  CAs catalyze the interconversion between CO2 to bicarbonate ions, and serves as an 
important regulator of respiration, pH, CO2 homeostasis, and electrolyte secretion.  Due to 
potential side effects associated with sulfamate based inhibitors, other classes of inhibitors for 
STS are currently being explored (Nussbaumer and Billich, 2004) 
 
1.4 Substrate Inhibition 
1.4.1 4-DFMES unique irreversible inhibitor 
During the course of our studies on the development of irreversible inhibitors of STS, 
we developed 4-difluoromethylestrone sulfate (1.26) as a suicide inhibitor for STS (Ahmed et al., 
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2009). The mode of inhibition of 1.26 is unique in that it exhibits multiple pathways for 
irreversible STS inhibition (Scheme 1.3).  The compound undergoes hydrolysis by the enzyme 
to produce inorganic sulfate and 4-difluromethylestrone (1.27).  1.27 then undergoes a 
spontaneous elimination of HF to produce quinine methide species 1.28.  This species can react 
with active site residues causing irreversible STS inhibition or it can diffuse out of the active site 
where it reacts with water to eventually give 4-formyl estrone (1.29). 1.29 then enters the active 
site and can also irreversibly inhibit STS.  How 1.29 irreversibly inhibits STS is not known, 





























































































Figure 1.10.  Time- and concentration-dependent inactivation of STS with 4-DFMES at 
concentrations 10 µM or less: 0 µM (◊); 1 µM □; 2.5 µM (○); 5 µM (■);7.5 µM (▲); 10 µM (●) 
(Ahmed et al., 2009).  
 
Figure 1.11.  Time- and concentration-dependent inactivation of STS with 4-DFMES at 
concentrations of 10 µM and greater: 0 µM (◊); 10 µM (□);20 µM (○); 40 µM (■); 80 µM (▲) 
(Chau, Ahmed and Taylor, unpublished results).  
 
As expected of most suicide inhibitors, the rate of inhibition of STS with 4-DFMES 
increases with increasing inhibitor concentrations (Figure 1.10).  Strangely enough, at 
concentrations greater than 10 µM, the rate of inhibition begins to decrease (Figure 1.11).  There 
are two possible explanations for this. One is that at higher 4-DFMES concentrations it takes 

































possible explanation is that there is substrate inhibition taking place as it has been reported that at 
substrate concentrations greater than 10 µM, STS begins to experience substrate inhibition (Prost 
et al., 1984; Dibbelt et al., 1994)   
 
1.4.2 Substrate Inhibition 
Enzyme kinetics for most part follow the Michaelis-Menten curve such that as substrate 
concentration increases, the rate of catalysis also increases until it begins to plateau nearing a 
threshold Vmax.  In some enzymes however, reaching a particular threshold concentration of 
substrate causes the rate to decrease; a phenomenon known as substrate inhibition (shown in 
Figure 1.12).  This phenomenon presents potential problems in data interpretation and 
extrapolation of enzyme kinetics, but at the same time can be exploited for inhibitor design (Lin 
et al., 2001). 
 
Figure 1.12.   The kinetics associated with substrate inhibition are slightly different than that of 




The phenomenon is not entirely uncommon as several different classes of enzymes 
exhibit substrate inhibition to some extent.  For example, some cytochrome P450 enzymes, 
responsible for catalyzing numerous endogenous substrates and xenobiotic, experience a 
reduction in activity from 39% up to 97% as a result of substrate inhibition (Lin et al., 2001). An 
important sulfotransferase enzyme, SULT1A1, which is involved in the sulfate conjugation of 
numerous endogenous compounds is also substrate inhibited by its xenobiotic substrates 
(Gamage et al., 2003).  Another example of an enzyme subject to substrate inhibition is 
adenosine 5’-phosphosulfate (APS) kinase, which catalyzes APS to 3’-phosphoadenosine 5’-
phosphosulfate (PAPS) (Sekulic et al., 2007). 
 
1.4.3 Substrate Inhibition in STS 
The kinetics observed with 4-DFMES suggest that STS may indeed be substrate 
inhibited.  In 1984, Prost et al. showed that concentrations of ES above approximately 7 µM 
resulted in substrate inhibition in STS (Prost et al., 1984). This same phenomenon was also later 
reported by Dibbelt et al. in 1994 who stated that STS is inhibited by its substrates such as ES 
(Km = 2-4 µM) at concentrations greater than 10 µM (Dibbelt et al., 1994) though no data was 
presented to support Dibbelt claim.  However, 4-methylumbelliferyl sulfate (4-MUS), a 
compound that is commonly used to assay STS activity, does not exhibit substrate inhibition.  
One argument to account for this exception is the structure of 4-MUS is very different than that 
of the natural substrate ES.   Hence, it may behave and bind differently than ES as suggested by 
its Km at 180 µM (Ahmed, 2009) which is substantially higher than that of ES.  Since Dibbelt et 
al., no studies have been done to validate the existence of this phenomenon or investigate the 
mechanism by which substrate inhibition within STS could occur.  In any case, the possibility of 
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substrate inhibition suggests additional binding sites which could potentially  be utilized for 
future inhibitor design.  Inextricably linked to the phenomenon of substrate inhibition in STS is 
the question of how STS substrates enter and leave the active site.  However, as discussed above, 
it is not known exactly how STS substrates and products enter and leave the active site   
 
1.5 Research Objectives 
The possibility that STS is subject to substrate inhibition suggests that it has multiple 
substrate binding sites.  The uncovering of non-active site binding sites for substrates and ligands 
could lead to the development of novel inhibitors that utilize these alternative sites.  The global 
objective of the work described in this thesis is to learn more about the presence of alternative 
substrate/ligand binding sites in STS.  In Chapter 2, we discuss the purification of STS and 
examine whether 2-nitroestrone sulfate can be use as chromogenic substrates for STS.  Such a 
chromogenic assay could potentially be used to readily study substrate inhibition in STS and 
would be a convenient alternative to the cumbersome radioassays used by Prost et al., and 
Dibbelt et al employing tritiated substrates.  In Chapter 3, we examine the inhibition of STS with 
various 4-substituted estrogen derivatives anticipating that these studies may indirectly reveal the 
existence of a secondary binding site.  Finally in Chapter 4, we determine whether a series of 
azido and diazo ES and EP derivatives can act as photoaffinity labels of STS.  Photoaffinity 
labels of STS could have potential for studying pathways of substrate entry and product release 





Chapter 2 – Purification and Assaying of Steroid Sulfatase  
2.1 Introduction 
 In order to assay STS accurately a pure form of the enzyme is required.  Impurities such 
as contaminating enzymes can yield unreliable results.  In addition, in some cases it is useful to 
know the exact concentration of STS such as in photoaffinity labeling studies.  There are only a 
few cases where researchers have used purified STS in their studies (Li et al., 1995; Dibbelt et 
al., 1994; Nussbaumer et al. 2002; Selcer et al., 1997).  While there have been efforts in the past 
to overexpress STS in E.coli, so far only limited success has been reported using 293-EBNA 
cells from human embryonic kidney cells (Stengel et al., 2008).  Hence, pure STS has 
traditionally been obtained by purifying it from human placenta, which is a good source of the 
enzyme.  Human placenta is readily available and no specialized equipment is required for STS 
extraction and purification.  There is a considerable number of published procedures on the 
purification of STS from human placenta, although the purification results in regards to 
enzymatic properties varies greatly amongst them (van der Loos et al., 1983; Noel et al., 1983; 
Burns et al., 1983; Dibbelt et al., 1986; Vaccaro et al., 1987;  Shakaran et al., 1991; Suzuki et al., 
1992; Purohit et al., 1998; Hernandez-Guzmen et al., 2003). Despite their differences, the initial 
steps in the process share common elements.  The first step always involves homogenization of 
the placenta followed by centrifugation of the homogenate which yields crude STS in the 
microsomal fraction.  The second process is the solubilization of the enzyme in the microsomal 
fraction using a detergent, such as Triton X-100.  The third involves the use of an anion 
exchange column to separate STS from other aryl sulfatases.  After this step, a wide variety of 
chromatographic media and techniques have been used to obtain the pure enzyme.  The objective 
of the work described in this chapter is to purify STS using a procedure developed by researchers 
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at Novartis and modified in the Taylor group (Ahmed et al., 2005). In addition we examine an 
alternative approach to assaying STS using a chromogenic substrate based on a natural steroidal 
substrate.   
 
2.2 Results and Discussion 
2.2.1 Placental Purification of STS 
STS was extracted from human placental based on procedures provided by (Hernandez-
Guzman et al., 2001) and purified using the procedure developed at Novartis and in the Taylor 
group (Ahmed et al., 2005).  Briefly, fresh placenta was homogenized and the resulting 
homogenate centrifuged to obtain the microsomal fractions which contained STS.  The fractions 
were solubilized in buffer containing Triton X-100, applied to a DEAE ion exchange column, 
and then eluted using a salt gradient.  Those fractions with STS activity, as determined by the 4-
MUS assay (as discussed in section 2.2.2 below) were pooled and dialyzed into buffer containing 
20 mM HEPES 1% Triton X-100 pH 7.4.  This sample was then applied to an immunoaffinity 
column containing a covalently bound anti-STS antibody that binds specifically to STS.  The 
column was washed with buffer to remove any residual protein that may bind non-specifically.  
Buffer containing 50mM citric acid, 140mM NaCl, 0.01% Triton X-100 at pH 2.7 is used to 
elute STS from the column, and fractions containing STS are pooled, dialyzed into 20 mM Tris-
HCl buffer, pH 7.0 containing 0.1% Triton X-100, and stored at -80 oC.  This procedure yields 
STS in high purity; two bands on the SDS page correspond to the two main glycosylation states 
of the enzyme (Figure 2.3).  The molecular mass of purified STS is approximately 63 kDA 
(Hernadez-Guzman et al., 2003; Stein et al., 1989; Sugawara et al., 2006).   The protein 
concentration was determined using a DC Protein Assay kit from BioRad Laboratories. The 
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specific activity of purified STS varied between purifications, from 0.5 to 1.25 µmol 4-
MUS/min/mg enzyme.  
 
 
Figure 2.1. Elution profile of STS activity by DEAE chromotography 
 
 















































































































Figure 2.3.  SDS PAGE of purified STS.  The gel was stained in Fermentas PageBlue Protein 
staining solution.  Lane 1 contains Fermentas PageRulerTM Prestained Protein Ladder.  Lane 2 
contains purified STS. 
 
2.2.2 2-Nitroestrone sulfate as a potential chromogenic substrate for STS 
STS is commonly assayed using the synthetic substrate 4-methylumbelliferyl sulfate (4-
MUS) between pH 7.0-8.0 (Scheme 1).  4-MUS is hydrolyzed by STS to give 4-
methylumbelliferone (MU), which in its ionized form, is fluorescent and can be measured by 




















Scheme 2.1.  The 4-methylumbelliferyl sulfate (4-MUS) assay for STS. 
As stated in Chapter 1, 4-MUS does not exhibit any apparent form of substrate 
inhibition, and one argument is because it does not resemble the natural substrate.  They exhibit 
significantly differences in Km’s: The Km for 4-MUS is 180 µM while that for ES is about 2-4 
µM (Ahmed, 2009).  For this reason, we believe that it is essential to use steroidal substrates 
which are structurally similar to ES, in order to study substrate inhibition in STS.  Unfortunately, 
the only method developed so far to assay STS using steroidal substrate involves the use of  
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radiolabelled steroidal substrates, such as tritiated estrone sulfate, combined with scintillation 
counting.  These types of assays were used by Prost et al., and Dibbelt et al. to report substrate 
inhibition in STS (Dibbelt et al., 1994; Prost et al., 1984). However, they are very expensive, 
time consuming and tedious to perform. 
One possible solution to assaying STS using steroidal substrates without resulting to 
radioassays is to use chromogenic steroidal substrates, and then using absorbance 
spectrophotometry to assay STS activity.  Nitrated compounds are commonly used to assay 
various enzymes by spectrophotometry, such as p-nitrophenylphosphate in assaying phosphatase 
activity (Tabatabai and Bremner, 1969) and 2-nitrophenol in assaying nitrophenol oxygenase in 







2-nitro phenolp-nitrophenyl phosphate  
Figure 2.4.   Structures of p-nitrophenyl phosphate and 2-nitrophenol (Folsom, 1997; Tabatabai 
and Bremner, 1969). 
 
From our previous studies, we noted that STS is able to accommodate small groups at 
the 2-position of the A-ring (Ahmed et al., 2009).  This suggests to us that 2-nitroestrone sulfate  
(2-NES) (Scheme 2) might act as a substrate for STS.  If 2-NES is a substrate for STS the S-O 
bond on 2-NES will be hydrolyzed to produce 2-nitroestrone (2-NE1, Scheme 2) and so it might 




Scheme 2.2.  Reaction of STS with 2-NES. 
2.2.2  Determination of the extinction coefficient of 2-NE1 and 2-NES 
Nourescu et al. have reported that in ethanol-water at pH 3.5, 2-NE1 has an λmax at 297 
nm with a corresponding molar extinction coefficient (ε) of 7940 M-1 cm-1, and an λmax at 425 
nm with an ε value of 5337 M-1 cm-1 at pH 13 (Nourescu et al., 1998). 2-nitrophenol has an ε of 
3470 M-1 cm-1 at pH 7.5 in phosphate buffer (Zeyer, 1986).  Although spectral data for 2-NE1 at 
pH 3.5 and 13 have been reported before, we decided reexamine this and to also to determine the 
molar extinction coefficients of 2-NE1 at pH’s more relevant to STS (pH 7-8).  2-NE1 and 2-
NES were prepared by Christine Nicholas in the Taylor Group.  The spectra data are summarized 
in Table 2.1. At pH 1.5 we noted an absorbance maximum at 300 nm.  At pH’s 7.5, 8.0 and 12.0 
two maxima were found at about 300 and 430 nm.  The extinction coefficient at pH 7.5 and pH 
8.0, pH’s at which STS is commonly assayed, at about 430 nm was 3200 M-1 cm-1 while at 299 
nm it was 7100 (pH 7.5) and 5200 M-1 cm-1 (pH 8.0).  2-NES exhibits an absorbance maximum 
at 281 nm with an extinction coefficient of 4200 M-1 cm-1, absorbs relatively strongly at 299 nm 
and does not absorb at 430 nm (Table 2).  So we decided to examine 2-NES as a substrate for 
STS at pH 8.0 monitoring the increase in absorbance at 433 nm even though the extinction 
coefficient of 2-NE1 at this wavelength was only 3200 cm-1.  If we use 50 µM 2-NES in the STS 
assay at pH 8.0 and if only 10% of the substrate were hydrolyzed we would only expect an OD 

















change. Indeed, when we incubated 9 nM STS with 50 µM 2-NES, we could not detect the 
production of 2-NE1 at 433 nm in buffer containing 10% ethanol, 0.01% Triton X-100 and 0.1 
M Tris-HCl at pH 8.0 in a 10 mm cuvette.  Hence, we expect that amount of 2-NE1 produced by 
STS may be too small to be reliably detected or 2-NES is not a substrate for STS.  
Table 2.1.  Spectra of 2-NE1 at various pH. Concentrations of 2-NE1 beginning 
at the bottom curve are 10, 40, 80, 120, 160, and 200 µM respectively for all pH 
except 7.5.  At pH 7.5, concentrations of 2-NE1 beginning at the bottom curve are 




























































































Figure 2.5. Replots of 2-NE1 spectra at pH 12 at wavelength 299nm () and 434 nm () 
 
 

















y = 0.0058x - 0.0149
R² = 0.9988













































Figure 2.7.  Replots of 2-NE1 spectra at pH 7.5 at wavelength 299 nm () and 431 nm ()  
 
 





y = 0.0071x + 0.0078
R² = 0.9895























y = 0.0051x + 0.0387
R² = 0.9899
























Table 2.2  Spectra of 2-NES at pH 8.  Concentrations of 2-NES beginning at 
the bottom curve are 20, 40, 60, 80, and 100µM.  
pH Spectra λmaxima 
(nm) 
Molar Extinction 













Figure 2.9.  Replots of 2-NES spectra at pH 8.0 at wavelength 232 nm () and 281 nm ()  
To determine if 2-NES is a substrate for STS we incubated 50 µM 2-NES with 9 nM 
STS in buffer containing 10% ethanol, 0.01% Triton X-100 and 0.1 M Tris-HCl at pH 8.0 and 
looked for the production of 2-NE at 281 and 299 nm using HPLC.  After 25 minutes all of the 
2NES is completely converted to 2-NE (Figures 2.10 and 2.11), suggesting that 2-NES is indeed 


















y = 0.0065x - 0.0558
R² = 0.9909























product, 2-NE1 is not a strong enough chromophore to allow 2-NES to be used as a chromogenic 
substrate for STS.   
 
F 
Figure 2.10. HPLC chromatograms for A) 2-NES; B) 2-NE1 and,  C) a solution containing 9 
nM STS, 50 µM 2-NES after 25 min.  A solutions were prepared in buffer containing 0.1 M Tris-
















Figure 2.11.  HPLC chromatograms for A) 2-NES; B) 2-NE1 and,  C) a solution containing 9 
nM STS, 50 µM 2-NES in buffer containing 0.1 M Tris-HCl, 0.01 % Triton X-100, 10% ethanol 
at pH 8.0 after 25 minutes. The detector was set to 299 nm. 
2.3 Conclusion and Future Work 
The purification of STS is an important first step for accurate kinetic analysis of STS 
activity.  In the Taylor lab, we have developed a reliable method for the purification of STS 
which yields the enzyme in very high purity.  While 2-NES is a substrate for STS, 2-NE is a not 
a sensitive enough chromophore to be used for the continuous assaying of STS. It looks like 















2.4.1 Materials  
 The biochemical reagents and buffers were purchased from Sigma-Aldrich (St. Louis, 
Missouri).  Fresh human placenta was provided by Credit Valley Hospital (Mississauga, 
Ontario).  The placenta is transported on dry ice and stored at -80oC for no longer than two days 
before its purification.  DEAE cellulose was purchased from Whatman (Maidstone, England).   
The STS immunoaffinity column was prepared by Vanessa Ahmed, a graduate student in the 
Taylor group, by coupling an anti-STS monoclonal antibody, obtained as a gift from Novartis 
(Austria), to cyanogen bromide-activated Sepharose 4B obtained from Pharmacia at a density of 
10mg/ml resin.  The procedure for purification of STS by immunoaffinity chromatography was 
provided by Dr. Andreas Billich at Novartis (Austria).  The DC Protein Assay kit was purchased 
from BioRad Laboratories (Richmond, California).  Gel staining was achieved by PageBlueTM 
Protein staining solution from Fermentas Life Science (Vilnius, Lithuania).  STS activity was 
determined, using the 4-MUS assay described above, on a SpectraMax Gemini XS plate reader 
from Molecular Devices (Sunnyvale, California) and analyzed with SOFTMAX Pro Version 
3.1.1 and Microsoft Excel 2007.  UV Spectra were obtained using an Agilent 8453 
Spectrophotometer (Santa Clara, California) in a 10 mm quartz cuvette from Hellma (Germany).  
2.4.2 STS purification 
 The homogenization and centrifugation of human placenta were done according to 
procedures developed by Hernadez-Guzman and coworkers (Hernandez-Guzman et al., 2003).  
After removal of the membrane and umbilical cord, the full-term human placenta was cut into 
small pieces. 200 g of the chopped up placenta was homogenized using a Brinkman polytron in 
50mM Tris-HCl pH 7.5, 0.25 sucrose, 1 g protease inhibitor cocktail (Sigma-Aldrich).  The 
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resulting homogenate, approximately 400 mL, was centrifuged at 20 000g for 30 min at 4oC.  
The supernatant was discarded, and the pellet resuspended in the same buffer, and subjected to 
another centrifugation at 20,000 g for 30 min at 4oC.  The supernatant was discarded again, and 
the pellet resuspended in 300 mL of extraction buffer consisting of 20 mM Tris-HCl, pH 7.4, 0.3 
% Triton X-100.  This sample is allowed to equilibrate for two hours before being subjected to 
ultracentrifugation at 100,000 g for 70 min at 4oC.  The time the supernatant was collected, and 
the pellet was resuspended in 200 mL of the extraction buffer and subjected to another 
ultracentrifugation.  The resulting supernatant was pooled with the previously collected 
supernatant, and the pellets were discarded.  This microsomal sample, approximately 400 mL, 
was dialyzed into buffer containing 20 mM Tris-HCl, pH 7.4, 0.1% Triton X-100 (3 x 4 L) over 
24 hours.  The dialysate was loaded onto a DEAE column (radius = 2.5 cm, height  = 16.5 cm), 
washed with 1500 mL of buffer containing 20 mM Tris-HCl, pH 7.4, 0.1% Triton X-100, and 
eluted off with a salt gradient reaching 1 M of NaCl in buffer 20 mM Tris-HCl, pH 7.4, 0.1% 
Triton X-100 over 1000 mL.  Pooled fractions containing STS (250 mL) were dialyzed into 20 
mM Hepes buffer pH 7.4 1% Triton X-100 (3 x 2 L) over 24 hours.  This material was applied to 
an anti-STS immunoaffinity column (2.5 mL) that had been pre-equilibrated with 25 mL of the 
Hepes dialysis buffer. The column was washed with 40 mL of the same buffer, and STS fractions 
are eluted off with 40 mL of 50 mM citric acid, 140 mM NaCl, 0.1% Triton X-100.  The 
fractions are pooled and dialyzed into storage buffer containing 20 mM Tris-HCl, pH 7.4, 0.1% 






2.4.3  STS activity in Purification 
STS activity in the fractions obtained at the various stages of the purification procedure 
was determined as follows.  20 µL sample was added into the wells of a 96-well black microtiter 
plate containing 180 µL of 222 µM 4-MUS in 0.1 M Tris-HCl, pH 7.0 such that the final 
concentration of STS was 10 fold diluted in buffer containing 200 µM 4-MUS 0.1 M Tris-HCl, 
pH 7.0 0.01% Triton X-100.  The production of fluorescent 4-MU was monitored for 5 minutes 
(λext = 360nm, λem = 460 nm) using a SpectraMax Gemini XS plate reader.  The enzyme activity 
was reported as relative fluorescent units per second (RFUs/second).   
2.4.4  Protein determination 
The protein concentration was determined according to DC Biorad Laboratories 
(Richmond, CA) protein concentration determination kit instructions using bovine serum 
albumin (BSA) as a standard.  This colorimetric assay is for the determination of protein 
concentration following solubilization with a detergent such as Triton X-100. The assay is based 
on the reaction of protein with an alkaline copper tartrate solution and Folin reagent (Bradford, 
1976). 
2.4.5  Spectral data 
 2 mM solutions of 2-NE1 and 2-NES were prepared in ethanol.  These solutions were 
diluted in buffer containing 0.11 M Tris-HCl, 0.011% Triton X-100 that was pH’d to the desired 
value (1.5, 7.5, 8.0 and 12).  Serial dilutions of these two stock solutions in the same buffer at the 
appropriate pH were performed to obtain the solutions that were used for spectral determinations.  
1 mL of these solutions was added to a 10 mm Helma cuvette and the spectra obtained using an 
Agilent 8453 spectrophotometer.  Solutions containing 0.1 M Tris-HCl, 10% ethanol, 0.01% 
Triton X-100 were used as blanks.  The extinction coefficients were determined by taking the 
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slopes of plots of OD versus concentration and fitting the data using linear regression analysis 
with Excel 2007.  
2.4.6  HPLC studies 
A solution of 9 nM STS and 50 µM 2-NES in buffer containing 0.1 M Tris-HCl, 0.01 
% Triton X-100, 10% ethanol, pH 8.0 was prepared and left standing at room temperature for 25 
min.  A 20 µL aliquot was withdrawn and injected on to a Phenomex Jupiter analytical reversed-
phase C-18 column (Torrance, CA, USA) attached to a Waters 600 HPLC system (Milford, MA, 
USA).  The Waters 2487 dual wavelength detector was set to 299 nm and 281 nm.  The 
compounds were eluted using 52% acetonitrile/48% water containing 0.1% trifluoroacetic acid.  
The retention times of 2-NES and 2-NE1 were determined by injecting 20 µL samples of 50 µM 





Chapter 3 – 4-Substituted Estrogens as Reversible and Irreversible 
Inhibitors of STS 
 
3.1 Introduction 
 In Chapter 1 we mentioned that 4-formyl estrone (1.29, Figure 3.1) was an irreversible 
inhibitor of STS (Ahmed et al., 2009).   Kitz-Wilson analysis yielded a KI of 1.5 µM and a kinact 
of 0.13 min-1 (kinact/KI = 1 x 10
5 M-1 min-1).  With just 5 µM of 4-FE1, STS is almost completely 
inactivated within 60 minutes.  Only 2 % of STS activity could be recovered after extensive 
dialysis.  We proposed that the compound forms a Schiff base with active site amine-bearing 
residues though this has yet to be proven.  What was also interesting was that 2-formyl estrone 
(2-FE1, 3.1) and estra-1,3,5(10)-triene-17-one-3-carbaldehyde (3.2) did not exhibit any 
inhibition at concentrations up to 10 µM indicating that the inhibition is specific for the formyl 















Figure 3.1.  Structures of 4- (1.29) and 2-formyl estrone (3.1) and estra-1,3,5(10)-triene-17-one-
3-carbaldehyde (3.2).   
 
 There have been almost no reports in the literature of STS inhibitors, reversible or 
irreversible, bearing substituents at the 4-position of E1 or E2.  The objective of the work 
described in this chapter is to examine estrogen derivatives bearing functional groups at the 4-




3.2 Results and Discussion 
3.2.1 Inhibition of STS with 17-α-benzyl-4-formyl estradiol 
 We wished to determine if we could improve upon the potency of 4-FE1 by modifying 
the steroid skeleton  As mentioned in Chapter 1, Poirier and coworkers have reported that 
estradiol modified at the 17-position with hydrophobic phenyl, benzyl or alkyl groups yields 
compounds that are highly potent reversible inhibitors of STS (see Table 1.2).  (Poirier et al. 
1998, Ciobanu and Poirier, 2006).  One example of such an inhibitor is compound 3.3 which has 
an IC50 value of 299 nM with purified STS (Ahmed et al., 2006) (Figure 3.2).  Based on 
Poirier’s work on 17-modified estradiol derivatives we decided to determine if the potency of 4-
FE1 could be improved by modifying 4-FE1 at the 17-position.  Towards this end, compound 3.4 







Figure 3.2.  Structures of compounds 3.3-3.4.   
 Incubation of STS with 3.4 resulted in time- and concentration-dependent inhibition as 
illustrated in Figure 3.3.  From the Kitz-Wilson plot (inset, Figure 3.3) a Ki of 107 nM and kinact 
of 0.025 min-1 were obtained indicating that this compound is considerably more potent than 4-
FE1 in terms of its affinity for STS but its rate of inactivation is less than that of 4-FE1.  
However, kinact/KI for 3.4 is 2.3 x 10
5 M-1 min-1 which is superiour to 4-FE1.  There are several 
other differences between compound 3.4 and 4-FE1.  When STS is incubated with low 
concentrations (< 1 µM) of 4-FE1 the inactivation plateaus after about 40 minutes while at 
higher concentrations (≥ 1 µM) pseudo-first order behaviour was observed throughout (Figure 
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3.4).  This behaviour may be due to multiple labelling events that are both productive and 
unproductive towards inactivation.  This behaviour was not seen with 3.4 as more or less pseudo-
first order behaviour was exhibited at all of the concentrations examined (Figure 3.3).  Also, 
after inactivation of STS with compound 3.4, about 14% of the activity was recovered after 
extensively dialyzing for 24 h (Figure 3.5).  This is in contrast to 4-FE1 where almost no activity 
could be recovered after inactivation.  Consequently, it is possible that these two inhibitors are 
targeting different residues.   
 
 
Figure 3.3.  Time- and concentration-dependent inhibition of STS with compound 3.4.  
Reactions were conducted in 0.1 M Tris-HCl 5 % DMSO 0.01 % Triton X-100 at pH 7.0 using 
310 nM STS.  STS activity was determined by adding 4-MUS to the reaction mixture such that 
the final concentration of 4-MUS was 4 mM and then the production of 4-MU followed using 







































Figure 3.5.   Dialysis experiment with 1µM 3.4 incubated with 277 nM STS in buffer containing 
0.1 M Tris-HCl, 5% DMSO, 0.1% Triton X-100  pH 7.0 in a 200 µL volume.  Samples are 
diluted 50-fold into a solution of the same buffer containing 4 mM 4-MUS at 0, 60, 540, 1200, 
and 1500 min.  The sample is dialyzed into a 1L buffer containing 0.1% Triton X-100 0.1 M 
Tris-HCl pH 7.0 every 8 h over a 24 h period beginning at time 60 min.    
 To determine whether compound 3.4 was labeling residues in the active site, a 
protection experiment was carried out with STS incubated with 2.5, 5, and 25 µM of EP in 0.1M 
Tris-HCl 5% DMSO pH 7.0.  The presence of EP, a competitive inhibitor of STS, protected the 

















































Figure 3.6.  Time- and concentration-dependent inhibition of STS with 500 nM 3.4 in the 
presence varying amounts of EP at 0 (), 2.5 (), 5(), 25 () µM.  A control was conducted 
in the absence of 3.4 and EP ().  Reactions were conducted in 0.1 M Tris-HCl, 5% DMSO 0.1 
% Triton X-100? at pH 7.0 using 310 nM STS.  STS activity was determined by adding 4-MUS 
to the reaction mixture such that the final concentration of 4-MUS was 4 mM and then the 
production of 4-MU followed using fluorimetry.   
 To determine if the inhibition was specific for the 4-position we examined compound 
3.5 (Figure 3.6, prepared by Byoungmoo Kim in the Taylor group) for STS inhibition.  This 
compound exhibited very little time- and concentration-dependent inhibition even at 10 µM 
(Figure 3.7).  The IC50 for this compound was not determined due to solubility issues greater 





Figure 3.7.  Structure of compound 3.5. 
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Figure 3.8.  Determination of time and concentration dependent inhibition of STS with 
compound 3.5.  Reactions were conducted as described in Figure 3.3.  [inhibitor]=0.1(), 1.0 





 We also examined several other 4-formyl estrogen derivatives for STS inhibition that 
had previously been prepared by Yong Liu in the Taylor group.  These 4-FE1 derivatives 
contained substituents at the 2-position and include the dialdehydes 3.8 and 3.9.  They were 
initially screened for time and concentration-dependent inhibition at 50 µM.  Surprisingly, none 
of these compounds exhibited time and concentration-dependent inhibition.  The IC50‘s were 
determined for compounds 3.7-3.9 (compounds 3.6 and 3.10 were poorly soluble in the assay 
buffer at concentrations greater than 50 µM) and found to be much greater than the KI of 4-FE1 
and compound 3.4.  Although this study is somewhat limited in scope, it suggests that 
substituents at the 2-position of 4-formyl estrogen derivatives have a detrimental effect on the 
binding of the inhibitor and the ability of the 2-formyl group to interact with a residue that results 
in time- and concentration dependent inhibition.  
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Table 3.1.  Inhibition of STS with 2-substituted 4-
FE1 Derivatives 
















































3.2.2  Reversible Inhibition of STS with 4-substituted estrogen derivatives 
 In addition to 4-formyl substituted estrogens, we also examined other 4-substituted 
estrogen derivatives as STS inhibitors which had been prepared in the Taylor group by Yong 
Liu.  These compounds and the results consisting of their percent inhibition (at 50 µM) and/or 
their IC50’s are shown in Table 3.2.  We reasoned that if a residue was forming a Schiff base 
with the aldehyde group of 4-FE1 then it might form a salt bridge with a carboxyl group at the 4-
position and a potent reversible inhibitor might result.  However, 4-carboxy estrone (3.11), was a 
very poor inhibitor.  The 4-hydroxymethyl, 4-aminomethyl and 4-amino derivatives (3.12-3.14) 
were also poor inhibitors as was the 4-vinyl derivative (3.15).  However, when we substituted the 
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4-position with a non-ionizable electron withdrawing group (compounds 3.16-3.20) the potency 
of these compounds increased considerably especially for the E1 derivatives.  The 4-NO2 E1 
derivative (3.19) exhibited the lowest IC50 (2.4 µM) from amongst this group of compounds.  4-
NO2-E2 (3.20) exhibited a similar IC50.  The 2-nitro (3.21), 2,4-dinitro (3.22) and the 4-nitro-2-
bromo derivatives (3.23) were all less potent than 3.19. The 2,4-dibromo derivative 3.24 was a 
surprisingly good inhibitor and almost as good as compound 3.19.   















% inhibition  
at 50 µM 
 
IC50 (µM) 
E1 H H C=O ND 51 ± 8 
E2 H H CHOH ND 11 ± 1 
3.11 CO2H H C=O 35 286 ± 13 
3.12 CH2OH H C=O 46 ND 
3.13 CH2NH2 H CHOH 4 ND 
3.14 NH2 H CHOH 43 ND 
3.15 CH=CH2 H C=O 45 ND 
3.16 Br H C=O 84 4.8 ± 0.4 
3.17 F H C=O 84 3.3 ± 0.2 
3.18 CN H C=O 71 6.7 ± 0.3 
3.19 NO2 H C=O 98 2.4 ± 0.1 
3.20 NO2 H CHOH ND 2.8 ± 0.2 
3.21 H NO2 C=O ND 17 ± 1 
3.22 NO2 NO2 C=O ND 26 ± 1 
3.23 NO2 Br C=O ND 9.5 ± 0.9 




 Studying the mode of reversible inhibition can help reveal secondary binding sites 
which may elicit inhibitory effects.  Here we briefly describe the modes of inhibition related to 
our project objectives.  The first is competitive inhibition, in which the inhibitor binds directly 
the active site.  As such, competitive inhibitors have the effect of diminishing the initial velocity 
of the catalytic reaction, and consequently increasing Km in the presence of the inhibitor.  The 
same Vmax however can still be achieved in the presence of excess substrates.  Non-competitive 
inhibitors have identical affinity to the free enzyme and the enzyme-substrate complex, and bind 
at a secondary site.  For this reason, they inhibit the enzyme by alternative mechanisms, and 
cannot be displaced by high substrate concentrations.  Non-competitive inhibitors consequently 
reduces the overall Vmax but Km  remains unchanged. In addition to these two types of inhibitors 
are mixed inhibitors, which can bind to both the active site and the secondary binding site 
(Copeland, 1996).  
 One way to study the modes of inhibition is by analyzing data using a Lineweaver-Burk 
Plot.  While there are other graphical determination methods available, the Lineweaver Burk 
Plot, or double-reciprocal plot of the Michaelis-Menten equation, is one of the commonly used 
transformation to analyze modes of inhibition.  In this plot, the y-axis represents 1/velocity and 
the x-axis corresponds to the 1/[substrate].  The y-intercept of these lines corresponds to the 
observed 1/Vmax and the x-intercept corresponds to -1/Km.  Typically, several experiments are 
conducted with various concentrations of substrate in the presence of different concentration of 
inhibitors.  The results are usually several lines which intersect at a particular point which reflect 
a particular inhibitor type.  Depending on the mode of inhibition, the observed Vmax and Km are 




Figure 3.9.   Lineweaver-Burk plot for competitive (A), non-competitive (B), and mixed 
inhibition (C) (Adapted from Copeland, 1996) 
 
 We investigated the mode of inhibition for compounds 3.19 (4-NO2E1), 3.16 (4-BrE1), 
and 3.20 (4-NO2E2) which were among the most potent ones listed in Table 3.2.  All three 
compounds showed almost exclusively non-competitive inhibition (Figures 3.9-3.11).  Replots 
of these graph to the corresponding Dixon-plot yielded non-competitive Ki for these compounds, 
and is displayed in Table 3.3.  So it appears that these compounds inhibit STS by binding at a 
secondary site and inhibit via a different mechanism than regular competitive inhibitors.  This is 
strong evidence suggesting the presence of a secondary binding site available to analogues of 





Figure 3.10.  Lineweaver-Burk plot for 3.19  0µM  0.5 µM  1 µM  2 µM 	 4 µM 
 










































Figure 3.12.  Lineweaver-Burk plot for 3.16  0µM  0.6125 µM  1.25 µM 2.5 µM 	 5 
µM   
 
Table 3.3.  Ki’s for compounds 3.19, 3.20 and 
3.24 





 If the above compounds are binding at a secondary site then the question remains as to 
where this second site is.  The detergent β-n-octyl-D-glucopyranoside (BOG, 3.25, Figure 3.12) 
is present during the crystallization of STS to help solubilize the enzyme (Hernandez-Guzman et 
al., 2001).  It co-crystallizes with STS.  It crystallizes in the tunnel formed by two 
transmembrane α-helices, and on a secondary site on the surface of the enzyme (Figure 3.13).  
The hydrophobic chain of BOG inserts itself in the hydrophobic tunnel towards the active site, 
suggesting a possible orientation for the substrate as it enters the active site or the product as it 
exits STS.  In vitro, the substrate may have access to this secondary binding site, which may be 
inhibitory, and result in the observed substrate inhibition at high concentration of substrate. It is 































Figure 3.13.  Structure of BOG 
 
Figure 3.14.  Crystal structure of STS showing the location of bound BOG (Hernadez-Guzman 
et al., 2003). 
 
3.3 Conclusion and Future Work 
 We have shown that the inhibition of STS with 4-formyl estrogen derivatives can be 
enhanced, in terms of binding affinity, by introducing a hydrophobic benzyl group at the 17-
positon of 4-FE1.  As with 4-FE1, the inhibition is still concentration and time-dependent.  
Future studies with these compounds will include determining if 4-FE1 and 3.4 are inhibiting 
STS by forming a Schiff base with a lysine or arginine residue.  These studies will involve 
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subjecting the inactivated enzyme to a reducing agent such as NaCNBH3 to reduce the imine (if 
formed) to a stable amine, followed by deglycosylation of the enzyme, enzymatic digestion and 
MS analysis of the resulting fragments. 
 Preliminary studies suggest that introducing substituents at the 2-position of 4-formyl 
estrogen derivatives results in loss of concentration and time-dependent inhibition and a 
considerable decrease in inhibitor affinity.  Studies with estrogen derivatives substituted at the 4-
position with groups other than a formyl revealed that a good reversible inhibitor can be obtained 
simply by introducing an electron withdrawing group at this position (such as 4-nitroestrone).  
However, these types of inhibitors are non-competitive inhibitors suggesting an alternative 
steroid binding site.  These compounds will be used as lead compounds for the design of future 
inhibitors for STS.  Preparing estrogens bearing substituents at both the 17- and 4-positions 
could lead to highly potent inhibitors.  
3.4 Experimental 
3.4.1  Materials 
 Materials were the same as described in section 2.4.1 chapter 2.   
3.4.2 IC50 determinations 
 20 µL of the inhibitor solutions of various concentrations of inhibitor in (1:1) 
DMSO/0.1 M Tris-HCl pH 7.0 were added to the wells of a 96-well microtiter plate containing 
160 µL of a 2 mM 4-MUS solution in 0.1 M Tris-HCl, pH 7.0.  The reaction is initiated by the 
addition of 20 µL of 80 nM STS in 20 mM Tris-HCl, pH 7.4, 0.1% Triton X-100 into to the well, 
yielding a final concentration of 8 nM STS, 200 µM 4-MUS in 0.1M Tris-HCl, pH 7.0, 0.01% 
Triton X-100, and 5% DMSO.  STS activity was measured by monitoring the production of 4-
MU by fluorescence for 10 minutes as described in section 2.4.3 in chapter 2.  The activity of 
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STS in the presence of inhibitor was compared to the activity of STS in the absence of inhibitor, 
and a percent activity was calculated.  This percent activity was plotted on a semi log graph 
against the log concentration of the inhibitor, and fitted in Grafit from Erithacus Software 
(Surrey, U.K.) using the equation: Vi = Vo/[1+([I]/IC50)S] + B where Vi = initial rate of reaction 
at inhibitor concentration [I]; Vo = velocity in the absence of inhibitor; B = background activity; 
s = slope factor.  All reactions were performed in triplicate. 
3.4.3 Ki determination  
Various solutions of inhibitors 3.19, 3.20, and 3.24 were prepared in DMSO/0.1M Tris-
HCl pH 7.0 (1:1).  20 µL of these solutions were added to the wells of a black 96-well microtiter 
containing 160 µL of varying concentrations of 4-MUS ranging from 0-222.2 µM.  The reaction 
is initiated by the addition of 20 µL of 80 nM STS in buffer containing 20 mM Tris-HCl 0.1% 
Triton X-100 pH 7.0. STS activity was monitored as described previously.  A positive control 
was done in a similar manner, with the exception of adding STS and replacing the volume with 
20 µL of 20mM Tris-HCl, 0.1% Triton X-100, pH 7.0.  The initial rates of the reaction obtained 
as relative fluorescent units over time (RFU/sec) for each 4-MUS concentration are plotted as a 
Lineweaver-Burk graph using Excel 2007.  The slopes and intercepts of the Lineweaver-Burk 
plots are replotted based on the equations for mixed or competitive inhibition to obtain the 
desired Ki values. All reactions were performed in triplicate. 
3.4.4 Determination of time and concentration dependent inhibition of STS with 3.4. 
 Stock solutions of compound 3.4 were prepared in DMSO/0.1M Tris-HCl pH 7.0 (1:1).  
20 µL of these samples were added to an Eppendorf tube containing 160 µL of 0.1M Tris-HCl 
pH 7.0 and 20 µL of 3.1 µM STS in 20 mM Tris-HCl, 0.1% Triton X-100 pH 7.4.  4 µL aliquots 
were withdrawn every 10 minutes and added to a well containing 196 µL of 4 mM 4-MUS in 0.1 
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M Tris-HCl pH 7.0.  This was repeated in triplicate.  STS activity was determined as described 
above.  A similar procedure was carried out for a control which contained 20 µL of DMSO/0.1 
M Tris-HCl pH 7.0 (1:1) in place of the inhibitor solutions.  The production of 4-MU was followed 
as described above.  The percent activity remaining as a function of time was plotted as a semilog graph.  
The slopes of these plots, which represent the pseudo-first order rate constants (kobs), were used to 
generate a Kitz-Wilson double reciprocal plot.  A linear regression model was used to calculate the 
inhibition constant, KI (-1/x-intercept) and kinact (1/y-intercept).  
3.4.5 Time and concentration-dependent inhibition of STS in the presence of estrone 
phosphate (EP) (protection experiments) 
Protection experiments with EP were carried out in the same procedures as above for 
time and concentration-dependent inhibition of compounds 3.4, with the exception of varying 
concentration of EP (2.5, 5, and 25µM).  The concentration of 3.4 was 500 nM.  
3.4.6 Dialysis Experiment  
 A 200 µL solution containing 1 µM of 3.4 and 277 nM STS in 0.1M Tris-HCl, 5% 
DMSO, 0.1 % Triton X-100, pH 7.0 was incubated for 60 minutes at room temperature. 4 µL 
aliquots were withdrawn at t = 0 and t = 60 min and added to the wells of a 96-well microtiter 
plate containing 196 µL of 4 mM 4-MUS. STS activity is monitored as described previously.  
This was performed in triplicate.  The remaining 176 µL was transferred to a dialysis bag and 
dialyzed against 1 L buffer containing 0.1 M Tris-HCl pH 7.0, 0.1% Triton X-100.  4 µL aliquots 
were withdrawn at 540, 1020, and 1500 min and STS activity was determined as described 
above.  After withdrawing aliquots at 540 and 1020 minutes the dialysis buffer was changed.  A 




Chapter 4 – Photoaffinity Labeling to Reveal Mode of Substrate and 
Product Transport in STS 
 
4.1 Introduction 
4.1.1 Photoaffinity labeling  
In Chapter 1 we mentioned that it is not yet known how STS substrates enter the active 
site (see section 1.2.3).  The substrate could enter via a tunnel between the two antiparallel 
hydrophobic α-helices.  Alternatively, the tunnel could also serve as an exit for the product.  An 
alternative mode of entry to the active site is for the substrate to enter from the lumen side via 
three flexible loops surrounding the active site.  In order for this to occur, the sulfated substrate 
must first be transported through the ERit membrane via a specific transporter into the lumen of 
the ERit.  One technique that may allow us to learn more about substrate entry and product 
release in STS is photoaffinity labeling.   
Photoaffinity labeling (PAL) is a labeling procedure which can be used to gain insight 
on ligand-protein interaction, such as drug-protein or substrate-protein interactions, otherwise not 
possible with regular protein identification and characterization techniques.  In brief, PAL 
involves a ligand containing a photosensitive group which is able to form a non-covalent 
interaction with its receptor.  As such, majority of photoaffinity labels are derivatives of natural 
substrates.  When activated by UV irradiation, the ligand breaks down to form a reactive 
intermediate which reacts to form a covalent bond with residues near the binding site.  The 
covalently linked ligand-receptor complex formed by PAL allows for vigorous downstream 
applications such SDS-PAGE, protein digests, HPLC, and mass spectrometry (Robinette et al., 
2006) (Figure 4.1).  These techniques, in particular mass spectrometry, when combined with 
PAL can reveal secondary binding sites and mode of substrate-protein interactions.  Amongst 
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other cross linking methods, PAL remains attractive due to its formation of highly reactive 
intermediates, capable of virtually reacting with any residues in proximity (Robinette et al., 
2006). In addition, PAL has been successful in the past to label various binding sites on proteins, 












Figure 4.1.  The photolabelled ligand is covalently linked by UV irradiation to the binding site 
on the enzyme.  The digestion of the labeled protein followed by MS allows for the identification 
of the labeled amino acids (Robinette et al., 2006) 
 
4.1.2 Photoaffinity Probes 
 The choice of a photoaffinity probe depends on the compatibility with the ligand and 
receptor in question.  Ideally, the photo label should have a lifespan under UV irradiation that is 
short enough so the covalent linkage can occur before the dissociation of the ligand-protein 
complex, but also long enough so that sufficiently covalent bonding is able to occur.  In addition, 
it should be able to attack C-H and X-H bonds at wavelengths that do not cause extensive 
photolytic damage to the protein.  The three main types of photoactivating groups commonly 
used in PAL are the benzophenone groups, diazirines, and azido.  Photolysis of these groups 
generally produces highly reactive carbenes and nitrenes.  A general reaction scheme for an 
azido group is shown in scheme 4.1.  These intermediates are highly reactive electrophiles 
capable of reacting with double bonds and heteroatoms with lone pairs such as nitrogen, oxygen, 
and sulfur.  However, their star role in PAL is due to their ability to attack inert aliphatic C-H 
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Scheme 4.1.  General mechanism for photoaffinity labeling of proteins with aryl azides 
 The objective of the work described in this chapter is to evaluate compounds 4.1-4.5 
(Figure 4.2) as photoaffinity labels of STS.  Should any of these compounds prove to be 
photoaffinity labels of STS then, by identifying which residues are being modified by these 




















































4.2 Results and Discussion 
4.2.1 Studies with compounds 4.1 and 4.2 
 We initially focused our attention on phenyl azides 4.1 and 4.2 which were synthesized 
by Christine Nicolas in the Taylor group.   We initially chose these compounds since it is known 
that phenylazides can be photolyzed under mild conditions (wavelengths between 300-350 nm 
are often employed [Payne et al., 1980]).  However, we did not know what affect irradiating STS 
at wavelengths between 300-350 nm would have on its activity.   To determine this a solution of 
STS in 0.1M Tris-HCl, 0.01% Triton X-100, 5% DMSO, pH 7.0 was irradiated at room lighting 
(control), 300 nm and 350 nm over 25 minutes (Figure 4.3) using a Rayonet Photochemical 
Reactor (Southern New England Ultraviolet).  At 300 nm irradiation, almost 45% of enzyme 
activity is lost over 25 minutes which is considerable.  The loss of activity at 350 nm was about 
15%, which is reasonably acceptable and thus selected as the irradiation wavelength for the PAL 
experiments.  
 
Figure 4.3.  Effect of irradiation at 300 or 350 nm on the activity of STS.  300 nm ()350 nm 

























 The next step was to determine if 4.1 and 4.2 breakdown within a reasonable amount of 
time (30 min) upon irradiation at 350 nm. Thus, estrone sulfate (ES), 4.1 and 4.2 were irradiated 
at 350 nm and their absorbance spectrum was obtained every 5 minutes over a 20 minute period 
(Figure 4.4-4.6).  4.1 and 4.2 exhibit absorbance maxima at around 250-260 nm (Figures 4.4 
and 4.5).  Although neither of these compounds absorb at 350 nm there was a significant change 
in their absorbance spectrum upon irradiation at 350 nm over the 20 minute time period 
suggesting that breakdown of the azide was occurring.   The spectrum of ES did not change upon 
irradiation at 350 nm (Figure 4.5).  
 
Figure 4.4.  Absorbance spectra of a 30 µM solution of 4.1 in 0.1M Tris-HCl, 0.01% Triton X-



















Figure 4.5.  Absorbance spectra of a 30 µM solution of 4.2 in 0.1M Tris-HCl, 0.01% Triton X-
100, 5% DMSO, pH 7.0 at 350 nm for 0, 5, 10, 15, 20 and 25 min. 
 
 
Figure 4.6.  Absorbance spectra of 50µM ES in 0.1 M Tris-HCl, 0.01% Triton X-100, 5% 
DMSO, pH 7.0   
 
 One potential complication of using 4.1 and 4.2 as PAL’s for STS is that they are 













































azidoestrone (4.7) which could also act as photolabels of STS (Figure 4.7).  Indeed, compound 































Figure 4.7.   Products (4.6 and 4.7) resulting from the STS-catalyzed hydrolysis of 4.1, and 4.2.  
 Compounds 4.6 and 4.7 were prepared in the Taylor lab by Christine Nicolas.  
Compound 4.6 was readily soluble in our assay buffer. Its absorbance spectrum was obtained and 
one of its absorption maxima is at 299 nm (Figure 4.8).  We also found that its spectrum 
undergoes considerable changes upon irradiation at 350 nm (Figure 4.8).  Compound 4.7 did not 
dissolve at all in our assay buffer and we had to obtain its spectrum in pure ethanol.  
Nevertheless, 4.7 appears to also absorb strongly at around 295 nm and there was an observable 




Figure 4.8.  Absorbance spectra of a 50 µM solution of 4.6 in 0.1M Tris-HCl, 0.01% Triton X-
100, 5% DMSO, pH 7.0 after irradiation at 350 nm for 0, 5, 10, 15, 20 and 25 min. 
 
Figure 4.9.  Absorbance spectra of a 50 µM solution of 4.7 in ethanol after irradiation at 350 nm 
for 0, 5, 10, 15, 20 and 25 min 
 
To find out if 4.1 and 4.2 were substrates for STS, we incubated 50 µM 4.1 and 4.2 with 
55 nM of STS in buffer containing 0.1 M Tris-HCl, 0.01 % Triton X-100, 5% DMSO at pH 7.0.  



















































After 25 minutes, 20 µL of each sample were injected into HPLC and their HPLC 
chromatograms obtained (Figures 4.10 and 4.11).  The samples were monitored at 255 nm, 
corresponding to the λmax of 4.1 and 4.2, (Figure 4.10) and 299 nm corresponding to the λmax of 
4.6 and one of the peaks of 4.7 (Figure 4.11).  After 25 minutes, almost all of 4.1 was consumed.  
In contrast, almost none of 4.2 was consumed.  So it appears that 4.1 is a substrate for STS while 
4.2 is not.   
 
Figure 4.10.  HPLC chromatograms for A) 50 µM 4.1 (left) or 4.2 (right) B) 50 µM 4.6 (left) or 
4.7 (right) C) 55 nM STS with 50 µM 4.1 (left) or 4.2 (right) after 25 minutes.  All solutions 
consisted of compound in 0.1 M Tris-HCl, 0.01 % Triton X-100, 5% DMSO, pH 7.0 prior to 





Figure 4.11.  HPLC chromatograms for A) 50 µM 4.1 (left) or 4.2 (right) B) 50 µM 4.6 (left) or 
4.7 (right) C) 55 nM STS with 50 µM 4.1 (left) or 4.2 (right) after 25 minutes.  All solutions 
consisted of compound in 0.1 M Tris-HCl, 0.01 % Triton X-100, 5% DMSO, pH 7.0 prior to 
injection into the HPLC.  Chromatograms were recorded at 299 nm. 
 
 Although compound 4.2 is not an STS substrate, we did find that it is a good STS 
inhibitor exhibiting an IC50 of 7.4 ± 0.4 µM.  A more detailed analysis revealed that this 
compound exhibits mixed non-competitive inhibition (Figure 4.12) with a Ki of 8.3 µM and αKi 
of 19.5µM.  So this compound binds to STS but is not a substrate.  It is not surprising that this 
compound exhibits mixed non-competitive inhibition since we demonstrated in Chapter 3 that 
estrogen derivatives bearing substituents at the 4-position were noncompetitive STS inhibitors.  
We also found that the IC50 for compound 4.1 (IC50= 8.3 ± 0.2 µM) is very similar to that of 
compound 4.2.  Compound 4.1 exhibits mainly competitive inhibition with a Ki of approximately 
5.5 µM (Figure 4.13) which is consistent with it being a good STS substrate.  However, the fact 
that it is a substrate for STS means that the IC50 and Ki values that we have reported for 4.1 must 
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be regarded with caution since its concentration would be changing (due to STS-catalyzed 
hydrolysis) during the course of the inhibition experiments.  
 
Figure 4.12. Lineweaver-Burk plot for 4.2  0µM  5 µM  10 µM  20 µM  
 
Figure 4.13.  Lineweaver-Burk plot for 4.1.  0µM (), 2.5 µM (),  5 µM  10 µM  
 Before examining 4.1 and 4.2, as well as 4.6 and 4.7 as PAL’s, we determined whether 















































350 nm.  10 µM (compound 4.7) or 50 µM (compounds 4.1, 4.2 and 4.6) of these compounds 
was incubated with STS in buffer containing 0.1M Tris-HCl 5% DMSO pH 7.0, aliquots were 
removed at various time intervals and added to a 2mM solution of 4-MUS in the same buffer and 
the activity of the enzyme determined. We did not observe any time-dependent inhibition over 
25 minutes as shown in Figure 4.14. 
 
Figure 4.14.  Percent STS activity recovered versus time upon a ten-fold dilution of a solution of 
STS containing no photoaffinity label (), 50 µM 4.1 (), 50 µM 4.2 (), 50 µM 4.6 (
) or 10 
µM 4.7 () into a solution of 2 mM 4-MUS.  All solutions contained 0.1 M Tris-HCl, 5% 
DMSO at pH 7.0. 
 
 Preliminary photoaffinity labeling experiments were carried out using varying 
concentrations of 4.1 and 4.2 ranging from 0-100 µM over 20 minutes with 30 nm STS to 
determine an ideal concentration of photoaffinity label to use.  The compounds were incubated 
with STS in buffer and the solution irradiated at 350 nm.  An aliquot was withdrawn every 5 
minutes and transferred to a solution containing 2 mM of 4-MUS and STS activity was 
determined in the usual manner.  Both compounds exhibited time- and concentration-dependent 
inhibition when irradiated at 350nm (Figure 4.15 and 4.16).  In both cases, we observe that 50 

























     
 
Figure 4.15.  Percent STS activity remaining versus time in the absence of 4.1 with no 
irradiation () and upon irradiation at 350 nm in the presence of 5(), 10(), 25 (), 50 () 
and 100 () µM 4.1 in 0.1M Tris-HCl, 2% DMSO, pH 7.0.  STS activity was determined by 
diluting the mixtures ten-fold into a solution containing 2 mM 4-MUS and following the 
production of MU as described in the experimental section.  Activity loss due to the effect of 350 



















































Figure 4.16.  Percent STS activity remaining versus time in the absence of 4.2 with no 
irradiation () and upon irradiation at 350 nm in the presence of 5(), 10(), 25 (), 50 () 
and 100 () µM 4.2 in 0.1M Tris-HCl, 2% DMSO, pH 7.0.  STS activity was determined by 
diluting the mixtures ten-fold into a solution containing 2 mM 4-MUS and following the 
production of MU as described in the experimental section.  Activity loss due to the effect of 350 
nM radiation on STS alone (see Figure 4.3) has been subtracted from the data.    
 
Photoaffinity of 4.1 and 4.2 with the above procedures produced very desirable results.  
We observe that for both compounds, the inhibition generally plateaus after 20 minutes. This is 
likely due to the complete breakdown of the photoaffinity label in solution.   We also note that 
4.1 exhibits a sharper decline in activity compared to that of 4.2, which exhibits an initial lag 
phase.  Overall, both 4.1 and 4.2 appear to be effective photoaffinity labels, with 4.1 only being 
slightly better.  We also examined the effect of DMSO on their ability to label STS by repeating 
the above experiments using 5% instead of 2% DMSO.  Increasing the DMSO from 2 to 5% had 
little or no effect on the ability of these compounds to label STS (Figure 4.17).    
 
 
Figure 4.17.  Percent STS activity remaining versus time in the absence of 4.1 and 4.2 with no 
irradiation (■), and in the presence of 50 µM (♦) 4.1 or 50 µM 4.2 (▲) in 0.1M Tris-HCl, 5% 
DMSO, pH 7.0.  STS activity was determined by diluting the mixtures ten-fold into a solution 
containing 2 mM 4-MUS and following the production of MU as described in the experimental 
section.  Activity loss due to the effect of 350 nM radiation on STS alone (see Figure 4.3) has 






























 One complicating issue when using 4.1 and 4.2 as photoaffinity labels is that the STS 
hydrolysis products 4.6 and 4.7 can also potentially act as photoaffinity labels.  This is not a 
major problem with 4.2 since it does not appear to be a good substrate.  However, 4.1 is a good 
substrate and is certainly being hydrolyzed under the conditions of the PAL experiment.  
Therefore we checked whether 4.6 and 4.7 could act as photoaffinity labels of STS.  While we 
were able to solubilize 4.6 at 50 µM, we were unable to do so for 4.7 at concentrations greater 
than 10 µM.  The data in Figure 4.18 reveal that 4.6 is a good photoaffinity label for STS.  
Compound 4.7 also appears (Figure 4.19) to be capable of labeling STS though the loss of 
activity is very small but this could be due to the fact that we are using a much lower 
concentration of label compared to what was used for our studies with 4.1, 4.2 and 4.6.  Thus 
using 4.1 as a photoaffinity label is not ideal since labeling by the desulfated product can also 
occur and it is very possible that the loss of activity we observe with 4.1 (Figure 4.16) may be 
completely due to labeling by 4.6.   However, since 4.3 labels STS fairly well and is not a good 
substrate it could be a promising photoaffinity label for STS.  One drawback of 4.3 is that it 
begins to experience solubility problems above 50µM, and hence can only be used as 




Figure 4.18.  Percent STS activity remaining versus time in the absence of 4.6 and 4.7 with no 
irradiation (■) and upon irradiation at 350 nm and in the presence of 50 µM 4.6 (♦) or 10 µM 4.7 
(▲) in 0.1M Tris-HCl, 5% DMSO, pH 7.0.  STS activity was determined by diluting the 
mixtures ten-fold into a solution containing 2 mM 4-MUS and following the production of MU 
as described in the experimental section.  Activity loss due to the effect of 350 nM radiation on 
STS alone (see Figure 4.3) has been subtracted from the data obtained from radiated solutions.  
 
4.2.2 Studies with compounds 4.3-4.5 
 One way to avoid the problem of the STS-catalyzed hydrolysis of the photoaffinity labels 
is to use photoaffinity labels that are based on an STS inhibitor instead of an STS substrate.  
Estrone-3-phosphate (EP, the phosphate analog of the natural STS substrate, ES) is a well-known 
inhibitor of STS with a Ki of 0.4 µM at pH 7.0 (Li et al., 1995).;  Therefore we decided to 
examine compounds 4.3-4.5 as PAL’s for STS (Figure 4.2).  These compounds should bind 
(non-covalently) to STS at least as well as 4.1 and 4.2 and they should be more soluble in 
solution due to the phosphate group.  Unlike compounds 4.1-4.4, diazoketone 4.5 should 
inactivate STS by forming a reactive carbene (not a nitrene) upon irradiation.  Carbenes are 
highly reactive compounds that can insert into C-H bonds.  Compound 4.5 is very similar to 







































Figure 4.19.  Structure of compound 4.8. 
 As with the first generation of photoaffinity labels, we carried out experiments to check 
whether EP and 4.3-4.5 break down upon irradiation at 350 nm (Figures 4.20-4.23).   
Compounds 4.3-4.5 exhibit significant changes in their absorbance spectra upon irradiation at 
350 nm suggesting that structural changes are indeed occurring upon irradiation (Figures 4.20-
4.22). The spectrum of EP did not change upon irradiation at 350 nm (Figure 4.23).  
 
Figure 4.20.  Absorbance spectra of a 50 µM solution of 4.3 in 0.1M Tris-HCl, 0.01% Triton X-































Figure 4.21.  Absorbance spectra of a 50 µM solution of 4.4 in 0.1M Tris-HCl, 0.01% Triton X-
100, 5% DMSO, pH 7.0 after irradiation at 350 nm for 0, 5, 10, 15, 20 and 30 min. 
 
 
Figure 4.22.  Absorbance spectra of a 200 µM solution of 4.5 in 0.1M Tris-HCl, 0.01% Triton 



























































Figure 4.23.  Absorbance spectra of 50 µM EP in 0.1M Tris-HCl, 0.01% Triton X-100, 5% 
DMSO, pH 7.0. 
 
 The change in the absorbance spectrum of compound 4.8 upon irradiation at 350 nm was 
also examined.  Surprisingly, the absorbance spectrum for compound 4.8 exhibited relatively 
minor changes upon irradiation at 350 nm (Figure 4.24).  The  λmax and λmin stayed more or less 
the same throughout the time course of the experiment while the absorbance intensity decreased, 
but not to a large extent, across the spectrum and with time.  This is in contrast to its phosphate 

























Figure 4.24.  Absorbance spectra of a 50 µM solution of 4.8 in 0.1M Tris-HCl, 0.01% Triton X-
100, 5% DMSO, pH 7.0 after irradiation at 350 nm for 0, 5, 10, 15, 20 and 25 min. 
 
 To determine if compounds 4.3-4.5 and 4.8 exhibit time-dependent inhibition of STS in 
the absence of irradiation at 350 nm, 50 µM of each of these compounds was incubated with 
STS, aliquots were removed at various time intervals and then diluted 10-fold into a solution of 4 
mM 4-MUS for compounds 4.3 and 4.5, and 2mM 4-MUS for compounds 4.4 and 4.8, and the 
activity of the enzyme determined. Once again, we did not observe any time-dependent 
inhibition of STS in the absence of light (Figure 4.25).  Only 40 % of the activity was recovered 
when STS was incubated with compounds both 4.3 and 4.5.  This suggested to us that these two 
compounds were perhaps very potent reversible inhibitors of STS and 4 mM 4-MUS was unable 
to completely displace these compounds from the active site after the initial solutions were 






























Figure 4.25.  Percent STS activity recovered versus time upon a 1/10 dilution of a solution of 
STS containing no inhibitor (), 50 µM 4.8 (), 50 µM 4.3 (), 50 µM 4.5 (), or 50 µM 4.4 
() into a solution of 4 mM 4-MUS for compounds 4.3 and 4.5, and 2mM 4-MUS for 
compounds 4.4 and 4.8.  All solutions contained 0.1 M Tris-HCl, 5% DMSO at pH 7.0.  
 
 Compound 4.5 exhibited competitive inhibition with a Ki of 1.4 µM, which is very 
similar to that of EP (Figure 4.26).  Nonetheless, it was not a significantly better inhibitor than 
compounds 4.1 and 4.2 though these compounds exhibited, to varying extents, mixed inhibition.  
Compound 4.3 was also a competitive inhibitor with a Ki of 6.8 µM (Figure 4.27).  Our ability 
to recover only 40 % of STS activity when incubating STS 4.3 and 4.5 does not seem to be 
related to the presence of the diazo or azido group in these compounds since we found that we 
were only able to partially recover STS activity when incubating STS with 10 µM EP which has 
a Ki very similar to that of compound 4.5 (Figure 4.28).  An examination of the percent activity 
recovered versus 4-MUS concentration (Figure 4.28) after incubation of STS with just 10 µM 
EP or 4.5 revealed that the amount of activity recovered was dependent upon the concentration 
of 4-MUS.  So it appears that even a high concentration of 4-MUS is unable to displace these 
inhibitors (after a 1/10 dilution into 4 mM 4-MUS).  Compound 4.4 was a relatively poor 
























Ki of 64 µM and an αKi of 127 µM.  As shown in Figure 4.24, STS activity was readily 




Figure 4.26.  Lineweaver-Burk plot for 4.5.  0µM (), 3.13 µM (), 6.25 µM (),12.5 µM 
(), 25.0 µM (	). 
 
 












































Figure 4.28.  Effect of 4-MUS concentration on the recovery of STS activity after incubating 
STS with 10 µM EP()and  10 µM 4.5 ().STS activity was determined by diluting the 
mixtures of STS and EP or STS and 4.5 ten-fold into a solution containing various 
concentrations of  4-MUS and following the production of MU as described in the experimental 
section.  Control without inhibitor (). 
 
 
Figure 4.29.  Lineweaver-Burk plot for compound 4.4.  0 µM (), 50 µM (), 100 µM (), 
200 µM ().  
 
 To our surprise, we did not observe labeling occurring with 4.5 (Figure 4.30).  One 
immediate assumption is that the diazo group in 4.5 is not breaking down when irradiated at 350 
nm.  However, the data presented in Figure 4.22 suggests that it is indeed breaking down under 





































the diazo group is indeed forming a carbene but the carbene is not reacting with a residue on the 
enzyme and the resulting product may still be a good inhibitor of STS since the phosphate group 
and much of the steroid skeleton should still be intact.   
 
Figure 4.30.  Percent STS activity remaining versus time in the absence of 4.5 with no 
irradiation () and upon irradiation at 350 nm and in the presence of 50 µM 4.5 () in 0.1M 
Tris-HCl, 5% DMSO, pH 7.0. STS activity was determined by diluting the mixture ten-fold into 
a solution containing 4 mM 4-MUS and following the production of MU as described in the 
experimental section.  Activity loss due to the effect of 350 nm radiation on STS alone (see 
Figure 4.3) has been subtracted from the data obtained from radiated solution.  
 
 Surprisingly, photoaffinity labeling experiments with 4.8 reveal that it is able to label 
STS moderately as shown in Figure 4.31.  This suggests that compounds 4.5 and 4.8 bind very 
differently to STS.  The phosphate group may bind in a way that prevents the diazo group from 
reacting with the residues important in the transport or catalysis of STS.  Compound 4.8 has an 































Figure 4.31.  Percent STS activity remaining versus time in the absence of 4.8 with no 
irradiation () and upon irradiation at 350 nm and in the presence of 50 µM 4.8 () in 0.1 M 
Tris-HCl, 5% DMSO, pH 7.0. STS activity was determined by diluting the mixture ten-fold into 
a solution containing 2 mM 4-MUS and following the production of MU as described in the 
experimental section.  Activity loss due to the effect of 350 nm radiation on STS alone (see 
Figure 4.3) has been subtracted from the data obtained from radiated solution.  
 
 Photoaffinity labeling experiments with 4.3 yielded results that were similar to 4.5 
(Figure 4.31).  Since 4.6 is a good photoaffinity label for STS, it suggests that the phosphate 
group may indeed be the culprit preventing labeling from occurring.  As shown earlier (Figure 
4.20), 4.3 breaks down upon irradiation at 350 nm.  The fact that activity is slowly being restored 
over time suggests that degradation of the label occurring.  A reaction might be occurring 
between the photo-generated nitrene and the phosphate group which is in very close proximity.  
This results in destruction of the phosphate groups and loss of inhibitory activity.  Compound 4.4 
is a good photoaffinity label of STS (Figure 4.32) with only 35 % STS activity remaining after 
being irradiated in the presence of 50 µM 4.4 for 25 minutes.  This was surprising considering 
that this compound exhibited the poorest affinity for STS amongst all of the compounds studied.  

























occurring at a secondary site (a site other than the active site) and this is somehow affecting 
enzymatic activity.  
We conducted a protection experiment to determine if compound 4.4 is reacting with 
active site residues.  The experiment was done similar to previous PAL experiments, with the 
addition of varying concentrations of estrone phosphate, a competitive inhibitor.  Estrone 
phosphate protects STS from inactivation by 4.4 when irradiated at 350 nm (Figure 4.34) 
indicating that at least some labeling is occurring at the active site.  A summary of our results 
with compounds 4.1-4.8 is given in Table 4.1.   
 
 
Figure 4.32.  Percent STS activity remaining versus time in the absence of 4.3 with no 
irradiation () and upon irradiation at 350 nm and in the presence of 50 µM 4.3 () in 0.1 M 
Tris-HCl, 5% DMSO, pH 7.0. STS activity was determined by diluting the mixture ten-fold into 
a solution containing 4 mM 4-MUS and following the production of MU as described in the 
experimental section.  Activity loss due to the effect of 350 nm radiation on STS alone (see 



























Figure 4.33.  Percent STS activity remaining versus time in the absence of 4.4 with no 
irradiation () and upon irradiation at 350 nm and in the presence of 50 µM 4.4 () in 0.1 M 
Tris-HCl, 5% DMSO, pH 7.0. STS activity was determined by diluting the mixture ten-fold into 
a solution containing 2 mM 4-MUS and following the production of MU as described in the 
experimental section.  Activity loss due to the effect of 350 nm radiation on STS alone (see 
Figure 4.3) has been subtracted from the data obtained from radiated solution.  
 
 
Figure 4.34.  Percent STS activity remaining versus time in the absence of 4.4 with no 
irradiation () and upon irradiation at 350 nm and in the presence of 50 µM 4.4 and 0 µM EP 
(), 2.5 µM EP (), 5 µM EP (
), and 25 µM EP () in 0.1 M Tris-HCl, 5% DMSO, pH 7.0. 
STS activity was determined by diluting the mixture ten-fold into a solution containing 4 mM 4-















































loss due to the effect of 350 nm radiation on STS alone (see Figure 4.2) has been subtracted 
from the data obtained from radiated solution. 
 





















4.1 8.3 ± 0.2 5.5 55 Competitive Yes 
4.2 7.4 ± 0.4 8.3 
(αKi = 20) 
45 Mixed No 
4.3 8.3 ± 0.2 6.8 61d Competitive No 
4.4 129 ± 11 
 
64 
(αKi  = 127) 
35 Mixed No 
4.5 12.4 ± 0.4 1.4 47d Competitive No 
4.6 ND* NDc 58 ND No 
4.7 ND* NDc 87b ND No 
4.8 24 ± 3 ND 64 ND No 
aPercent activity remaining after irradiation of a solution of STS and 50 µM 
compound at 350 nm for 25 minutes followed by a 10-fold dilution into a 2 mM 
solution of 4-MUS for all compounds except 4.3 and 4.5 in which 4mM 4-MUS was 
used.  bOnly 10 µM of compound used due to limited solubility of the compound. 
cNot determined due to limited solubility. dTime-dependent inhibition was not 
observed upon irradiation. 
 
 Out of the five sulfated and phosphorylated compounds studied compounds 4.2 and 4.4 
are most promising.  While 4.1 appeared to photolabel STS it is very possible that this was due to 
labeling by its hydrolysis product 4.6. Compounds 4.3 and 4.5 did not exhibit time-dependent 
inhibition upon irradiation.  Compounds 4.6 and 4.7 also act as photolabels of STS and might be 
useful for examining product release pathways in STS.   
 
4.2.3  Deglycosylation of STS  
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 We would like to use mass spectrometry to determine which residues in STS are being 
modified by our photoaffinity labels.  This will require that the modified STS be deglycosylated 
before MS analysis.  STS is glycosylated at four Asn residues. Mortaud et al. report 
deglycosylation of STS by a N-glycosidase F (PNGase F) (Mortaud et al., 1995).  PNGase is an 
endoglycosidase that catalyzes the release of N-linked oligosaccharides from proteins (Tarentino 
et al., 1985).  We purchased PNGase F from New England Biolabs, and followed the procedure 
provided with the kit.  Mortaud et al. have shown that deglycosylated STS exhibits enhanced 
mobility on SDS PAGE compared to native STS and our results (Figure 4.35) are consistent 
with this observation.  PNGase usually appears on an SDS gel as 35.5 kDA (Tarentino et al., 
1985), but we did not observe any band in this region due to a low concentration of PNGase F 
used. 
 
Figure 4.35.  SDS PAGE of purified STS.  The gel was stained in Fermentas PageBlue Protein 
staining solution.  Lane 1 contains Fermentas PageRulerTM Prestained Protein Ladder.  Lane 2 
contains deglycosylated STS .  Lane 3 contains purified STS. 
 
4.3 Conclusion and Future Work 
A series of estrone derivatives were examined as photoaffinity labels of STS.  Of the 
sulfated and phosphorylated compounds examined, two of these compounds, 4.2 and 4.4 exhibit 
properties that are suitable for PAL studies with STS.  These labels may be useful for 
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ascertaining pathways of substrate entry into the STS active site.  All of the non-sulfated or non-
phosphorylated compounds 4.6-4.8, acted as photoaffinity labels to varying degrees.  These 
labels may be useful for ascertaining pathways of product release into the STS active site. Our 
future studies will involve identifying which residues are being modified using mass 
spectrometry.  We have shown, by SDS PAGE, that we can deglycosylate STS.  The band 
corresponding to the deglycosylated enzyme has been excised from the gel (Figure 4.35) and 
sent to The University of Guelph mass spectrometry facility where an in-gel tryptic digest has 
been performed and the resulting fragments sequenced by LC-MSMS.  The next step is to 
perform this type of analysis on the modified enzyme.   
4.4 Experimental 
4.4.1  Materials 
 Most materials were the same as described in section 2.4.1 chapter 2.  Photoaffinity 
labeling of STS is carried out in quartz test tubes using a Rayonet Photochemical  Reactor from 
Southern New England Ultraviolet (Branford, Connecticut).  PNGase F deglycosylation kit 
(glycerol free) was purchased from New England Biolabs (Ipswich, MA).   
4.4.2 Effect of 350 nm light on STS activity 
 30 nM of STS in buffer containing 0.1% Triton X-100, 0.1M Tris-HCl, pH 7.0 was 
exposed to irradiation at  300 or 350 nm over 25 minutes.  20 µL aliquots were withdrawn every 
5 min, beginning at t=0, and added to the wells of a microtiter plate containing 180 µL of 222.2 
µM 4-MUS in 0.1M Tris-HCl, pH 7.0.  STS activity was determined as described previously.  A 





4.4.3 Spectrophotometric studies with compounds 4.1-4.8 
 4.1-4.6 and 4.8 were dissolved in a solution of 5% DMSO, 0.1M Tris-HCl, pH 7.0 0.01 
% Triton X-100 to the desired concentration.  Compound 4.7 was insoluble in buffer and so 
solutions of this compound were prepared in pure ethanol.  1 mL of these solutions were added 
to a 10mm Helma quartz cuvette, and their spectra were obtained.  To determine the effect of 
350 nm light on their absorbance spectra, 6 mL of these solutions were placed in a quartz test 
tube, and irradiated at 350 nm.  1 mL of sample was withdrawn at various time intervals and 
their spectra determined as described above. Controls were performed where the compound 
solutions were not irradiated at 350 nm but instead just subjected to room light.   
4.4.4 Photoaffinity labeling procedure 
 Various solutions of 4.1, and 4.2 with 30 nM of STS in buffer containing 2% DMSO, 
0.1M Tris-HCl pH 7.0 in a 1 mL sample.  This sample is pipetted into a quartz test tube, and 
irradiated at 350 nm UV irradiation for 20 minutes in a Rayonet Photochemical Reactor 
(Southern New England Ultraviolet).  Simultaneously, a sample of STS in the same buffer is also 
pipetted into a quartz test tube.  Every 5 minute beginning at time 0, a 20 µL is withdrawn from 
each test tube and added to a well containing 180 µL of 2mM 4-MUS 0.1M Tris-HCl pH 7.0; 
this is repeated in triplicates.  The activity of STS determined as previously described above.  
The activity of STS in the presence of varying concentrations of photoaffinity label irradiated 
with UV light is compared to the activity of STS in the absence of photoaffinity label and UV 
irradiation.  The results are averaged, analyzed and plotted as percent Activity using Excel 2007.  
Similar conditions with the omission of UV irradiation were used to determine if the 
photoaffinity label reacted with STS in the absence of UV irradiation.    
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 1 mL solutions containing 50 µM 4.1-4.8 and 55 nM STS in buffer containing 5 % 
DMSO, 0.1M Tris-HCl, pH 7.0, 0.01 %Triton X-100 were irradiated at 350 nm UV irradiation 
for 25minutes. Every 5 min starting at t = 0 a 20 µL aliquot was withdrawn and added to a well 
of a 96-well microtiter plate containing 180 µL of 2 mM 4-MUS in 0.1 M Tris-HCl pH 7.0, with 
the exception of compounds 4.6 and 4.7 where 4 mM 4-MUS was used.  STS activity was 
determined as described previously.  The following controls were performed:  (A) the enzyme 
was incubated in the absence of compound and not irradiated at 350 nm; (B)  the enzyme was 
incubated with 50 µM of photoaffinity label but not irradiated at 350 nm; (C)  the enzyme 
irradiated at 350 nm in the absence of compound.  Any time-dependent inhibition over 25 
minutes by the compound in the absence of UV irradiation was calculated as (STS activity in 
control B)/( STS activity in control A)
 100%.  The % activity remaining as a result of specific 
photoaffinity labeling of STS by the compounds was determined by  [1- (STS activity in control 
C - STS incubated with 50 µM of compound irradiated at 350nm UV irradiation) / (STS activity 
in control A)] 
 100%.   
4.4.5  HPLC Studies with 4.1 and 4.2 
For standard studies of 4.1 and 4.2 elution off the HPLC, 20µL of 50 µM 4.1 or 4.2 in 
0.1 M Tris-HCl, 0.01 % Triton X-100 5% DMSO pH 7.0 are injected into a Phenomex Jupiter 
analytical reversed-phase C-18 column (Torrance, CA, USA) on a Waters 600 HPLC system 
(Milford, MA, USA). The Waters 2487 dual wavelength detector is set to 255 nm corresponding 
to the λmaxima of these compounds.  The elution is set to an isocratic elution of acetonitrile/0.1% 
trifluoroacetic Acid (TFA) water (5:5) for 45minutes.  
For enzymatic studies with compounds 4.1 and 4.2, 55nM STS is incubated with either 
50 µM 4.1 or 4.2 in buffer A containing 0.1 M Tris-HCl, 0.01 % Triton X-100, containing 5% 
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DMSO at pH 7.0after 10 minutes. 20µL of this sample is injected into the HPLC and eluted off 
in the same conditions as stated above.    
4.4.6 IC50  and Ki determinations  
 IC50  and Ki determinations were performed as described in section 3.4.2 and 3.4.3  
4.4.7  Deglycosylation of STS 
 The deglycosylation of STS is followed according to the protocol provided by the 
PNGase F deglycosylation kit from New Negland Biolabs (Ipswich, MA).  The procedure 
provided is based on the deglycosylation of 1-20 µg glycoprotein, and we modified linearly it to 
accommodate a larger amount of protein.  137µg of STS, obtained by taking 0.9mL of the 
purified STS stock solution (0.152mg/ml) was added to 100µL of the provided 10X glycoprotein 
denaturing buffer.  This solution was incubated for 100oC for 10minutes.  To this solution, 
130µL of the provided 10X G7 reaction buffer, 130µL of 10% NP40, and 5µL of PNGase was 
added to make a total volume of 1265µL.  The sample was incubated for 12 hours (instead of the 
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Appendix A.   
IC50 plots for compounds 3.3. 3.7-3.9, 3.11, 3.16-3.24, E1 and E2 and 
replots of the data in figures 3.10-3.12. 
 
 
Figure A.1 IC50 for compounds 3.3 = 299 ± 14 nM 
 
 
Figure A.2 IC50 for compounds 3.7 = 145 ± 11 µM 
nM Inhibitor







































Figure A.3 IC50 for compounds 3.8 = 224 ± 7 µM 
 

















































Figure A.5 IC50 for compounds 3.11 = 286 ± 13 µM 
 
Figure A.6 IC50 for compounds 3.16 = 4.8 ± 0.4µM 
µM Inhibitor
































Figure A.7 IC50 for compounds 3.17 = 3.3 ± 0.2µM 
 
Figure A.8 IC50 for compounds 3.18 = 6.7 ± 0.3µM 
µM Inhibitor






































Figure A.10 IC50 for compounds 3.20 = 2.8 ± 0.2µM 
 
µM Inhibitor
































Figure A.11 IC50 for compounds 3.21 = 17 ± 1 µM 
 
Figure A.12 IC50 for compounds 3.22 = 26 ± 1 µM 
µM Inhibitor

































Figure A.13 IC50 for compounds 3.23 = 9.5 ± 0.9µM 
 
 
Figure A.14 IC50 for compounds 3.24 = 3.0 ± 0.1µM 
 
µM Inhibitor

































Figure A.15 IC50 for compounds E1 = 51 ± 8 µM 
 
 
Figure A.16 IC50 for compounds E2 = 11 ± 1 µM 
 
µM Inhibitor
































Figure A.17 Replot of the data from Figure 3.10 to determine Ki of inhibitor 3.19 
(1.4µM) 
 
Figure A.18 Replot of the data from Figure 3.11 to determine Ki of inhibitor 3.20 
(1.8µM) 
 







































































IC50 plots for compounds 4.1-4.5. 4.8 and EP and replots of the data 
in figures 4.12, 4.13, 4.26, 4.27, 4.29 
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Figure B.1 IC50 for compounds 4.1 = 8.3 ± 0.2 µM 
 
Figure B.2 IC50 for compounds 4.2 = 7.4 ± 0.4 µM 
µM Inhibitor
































Figure B.3 IC50 for compounds 4.3 = 8.3 ± 0.2 µM 
 
















































Figure B.5 IC50 for compounds 4.5 = 12.4 ± 0.3 µM 
 
 




















































Figure B.8 Replot of the data from Figure 4.13 to determine Ki of inhibitor 4.1 (5.5µM) 
µM Inhibitor






































Figure B.9 Replot of the data from Figure 4.12 to determine αKi of inhibitor 4.2 (19.5µM) 
 
 






























































































Figure B.13 Replot of the data from Figure 4.29 to determine αKi of inhibitor 4.4 (127 µM) 
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